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In an exercise designed to reduce animal use, we analyzed the results of rat subchronic 
toxicity studies from 289 pharmaceutical compounds with the aim to predict the tumor 
outcome of carcinogenicity studies in this species. The results were obtained from the 
assessment reports available at the Medicines Evaluation Board of the Netherlands 
for 289 pharmaceutical compounds that had been shown to be non-genotoxic. One 
hundred forty-three of the 239 compounds not inducing putative preneoplastic lesions in 
the subchronic study did not induce tumors in the carcinogenicity study [true negatives 
(TNs)], whereas 96 compounds were categorized as false negatives (FNs) because 
tumors were observed in the carcinogenicity study. Of the remaining 50 compounds, 31 
showed preneoplastic lesions in the subchronic study and tumors in the carcinogenicity 
study [true positives (TPs)], and 19 only showed preneoplastic lesions in subchronic 
studies but no tumors in the carcinogenicity study [false positives (FPs)]. In addition, we 
then re-assessed the prediction of the tumor outcome by integrating the pharmacolog-
ical properties of these compounds. These pharmacological properties were evaluated 
with respect to the presence or absence of a direct or indirect proliferative action. We 
found support for the absence of cellular proliferation for 204 compounds (TN). For 
67 compounds, the presence of cellular hyperplasia as evidence for proliferative action 
could be found (TP). Therefore, this approach resulted in an ability to predict non-car-
cinogens at a success rate of 92% and the ability to detect carcinogens at 98%. The 
combined evaluation of pharmacological and histopathological endpoints eventually led 
Abbreviations: AB, antibiotics; ac, adenocarcinoma; ad, adenoma; AF, antifungal agents; adr, adrenals; astr, astrocytoma; AV, 
antivirals; bheam, benign hemangioma; bpha, benign pheochromocytoma; bm, bone marrow; bo, bone; br, brain; bthym, 
benign thymoma; ca, carcinoma; ce, cecum; col, colon; fad, fibroadenoma; FN, false negative; FP, false positive; gca, granulosa 
cell adenoma; hrt, heart; hsyst, hematopoietic system; islet, islet of Langerhans; kid, kidneys; leio, leiomyoma; leu, leukemia; 
li, liver; lip, lipoma; ln, lymph nodes; lu, lungs; lymph, lymphoma; mam, mammary glands; mel, melanoma; mes, mesentrium; 
most, malignant osteoma = osteosarcoma; mpha, malignant pheochromocytoma; NC, non-categorizable based on pharmaco-
logical target; NOS, not otherwise specified; NT, non-mammalian target in mammalian tissue; ova, ovaries; pan, pancreas; pap, 
papilloma; parathy, parathyroids; pit, pituitary; pros, prostate; sar, sarcoma; SCC, squamous cell carcinoma; schwan, schwan-
noma; SCP, squamous cell papilloma; soft t, soft tissue; spl, spleen; stom, stomach; tes, testes; thyr, thyroid; thym, thymus; TN, 
true negative; TP, true positive; tu, tumor; UGT, urogenital tract; ut, uterus; zymgl, Zymbal’s gland; ZZ, remaining compounds.
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iNTRODUCTiON
Specific regulatory requirements for carcinogenicity assessment 
of new pharmaceuticals are described in International Conference 
(now Council) on Harmonisation (ICH) guidance documents, 
i.e., ICH Guidelines M3(R2) (1), S1A (2), S1B (3), S1C(R2) (4), 
S2 (5), and S6(R1) (6).
Carcinogenicity studies are generally required for new phar-
maceuticals that would be administered for 6 months or longer, 
or in a frequent and intermittent manner. In general, a 2-year 
rat study, plus either an 18 (or 24)-month mouse study or an 
alternative 6- or 9-month study in transgenic mice, is requested 
for such compounds.
The current 2-year rodent carcinogenicity study design used 
since the mid-1960s has been the regulatory standard in the 
safety assessment of humans. These carcinogenicity studies are 
expensive and time-consuming animal tests required for the 
safety assessment of pharmaceutical compounds. However, 
there is considerable scientific doubt about the reliability of the 
rat bioassay. Too many compounds are positively enhancing a 
tumor response in these studies, which may simply be due to 
the long-term exposure of the animals to rather high doses of 
the test compound (7–9) rather than a true carcinogenic effect. 
Therefore, there is a continued and increasingly need to justify 
the 2-year rodent bioassay in an attempt to reduce animal num-
bers, time, and costs (10, 11). For this reason, pharmaceutical 
companies and regulatory bodies are aiming to find an alterna-
tive approach.
In light of concerns raised about the predictability of in vivo 
studies in general and the push for refinement, reduction, and 
replacement of animal studies, it is strongly recommended to re-
evaluate the suitability of the 2-year rodent bioassay as the best 
approach to predict human disease (12–21).
We have undertaken a retrospective study of pharmaceuticals 
with available rodent subchronic (3- to 6-month studies) and 
carcinogenicity data to test the hypothesis that it is possible to 
replace the current 2-year bioassay with a weight-of-evidence 
approach, i.e., by using evidence from all the non-clinical data 
available at the stage of development of a compound, usually at 
the end of Clinical Phase II, when a decision for conducting a 
2-year carcinogenicity study is usually taken. Data that contribute 
are the results of the subchronic toxicity studies, in combination 
with genotoxicity data and knowledge of pharmacodynamic 
properties relating to the mode of action.
Positive in  vivo genotoxicity tests are generally considered 
as indicative for a carcinogenic potency of a compound. Under 
REACH (22), classification as a mutagen category 1A or 1B allows 
a waiving of the carcinogenicity study, since the default presump-
tion is that a genotoxic mechanism for carcinogenicity is likely. 
The same is true for human pharmaceuticals, where the ICH S1A 
guideline indicates that in case of positive genotoxicity, no life-
time carcinogenicity studies are expected. Positivity in an assay 
for DNA reactivity will usually also preclude further development 
(23), unless the risk for genotoxicity is acceptable in view of the 
benefit of the compound.
Jacobs (24) examined the data from 13-week rat toxicity 
studies for the prediction of carcinogenicity outcome using 
60 pharmaceutical compounds. The data were obtained from 
a USA Food and Drug Administration (FDA) database. She 
concluded that various short-term indicators of carcinogenicity, 
such as hyperplasia, hypertrophy, greater organ weight, tissue 
degeneration or atrophy, and mineralization in a tissue, did not 
always result in tumors in that tissue, although (some of) these 
indicators are considered signs of potential carcinogenicity. The 
tissues examined were limited to the liver, kidneys, mammary 
glands, adrenals, urinary bladder, and lung.
Reddy et  al. (25) confirmed the conclusion of Jacobs (24) 
with a different dataset. They used a “whole animal response” 
instead of individual tissues, testing the hypothesis that evidence 
of absence of putative preneoplastic lesions in any tissue may 
accurately predict a compound’s lack of carcinogenic potential. 
In their view, the presence of treatment-related putative preneo-
plastic histopathological lesions is not a definitive indicator of a 
tumorigenic potential of a compound, but rather requires that a 
24-month rat carcinogenicity study has to be run and all tissues 
and organs should be collected and examined.
Sistare et al. (16) further evaluated the predictivity of histo-
pathological findings, considering risk factors for rat neoplasia 
(hypertrophy, hyperplasia, metaplasia, cell proliferation, foci of 
cellular alteration, and inflammation accompanied by recurrent 
cell necrosis and repair) that were observed microscopically 
in 6-month rat toxicity studies with the tumor outcomes in rat 
2-year carcinogenicity studies for 182 pharmaceuticals derived 
from 13 pharmaceutical companies. They concluded that the 
absence, rather than the presence, of the aforementioned putative 
preneoplastic histopathological changes in rats was a reliable pre-
dictor of tumor outcome in the corresponding tissue. The authors 
proposed that compounds demonstrating no genotoxicity, no 
to only 18 unknown outcomes (17 categorized as FN and 1 as FP), thereby enhancing 
both the negative and positive predictivity of an evaluation based upon histopathological 
evaluation only. The data show the added value of a consideration of the pharmacolog-
ical properties of compounds in relation to potential class effects, both in the negative 
and positive direction. A high negative and a high positive predictivity will both result in 
waiving the need for conducting 2-year rat carcinogenicity studies, if this is accepted 
by Regulatory Authorities, which will save large numbers of animals and reduce drug 
development costs and time.
Keywords: carcinogenicity, pharmacology, human pharmaceuticals, histopathology, predictivity
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evidence for hormonal mechanisms, and no histopathological 
changes pointing to a risk factor for rat neoplasia in any tissue 
(called NEGCARC approach) are considered rat non-carcinogens 
and can be exempted from the requirement for testing in a 2-year 
carcinogenicity study.
Assessors from EU Regulatory Authorities on human phar-
maceuticals started to evaluate this approach and this set of 
data by emphasizing the consideration of the pharmacological 
properties of each compound and relating these properties to 
the outcome of the rat carcinogenicity study. The dataset was 
extended with data from FDA and the Japanese Pharmaceutical 
Manufacturer’s Association, increasing the number of com-
pounds to 255 (26). Pharmacological properties appeared to 
be well associated with the outcome of the rat carcinogenicity 
study, both in a positive and negative direction. Classes such as 
β2-agonists and dopamine D2 antagonists were rather strongly 
associated with induction of mesovarian leiomyoma and mam-
mary gland tumors, respectively (26). In addition, compounds 
inducing liver-associated pathology appear to be important in 
predicting tumors in organs such as liver, thyroid, and testis. The 
enzymes responsible for metabolism are also important factors 
in this respect.
The present retrospective study is intended to gather informa-
tion independently from the dataset of Sistare et al. (16) to further 
test the hypothesis that a weight-of-evidence approach is possible 
in predicting the carcinogenic potential of human pharmaceuti-
cals based upon histopathological and pharmacological proper-
ties. We have used a more restrictive approach in the definition 
of putative preneoplastic changes as compared with Sistare et al. 
(16), which will be further discussed below.
MATeRiALS AND MeTHODS
Selection of Compounds
The rat subchronic toxicity and chronic carcinogenicity data used 
for this evaluation came from the assessment reports that are 
available at the Medicines Evaluation Board of the Netherlands. 
The compounds and studies that were included were those in the 
paper of Van Oosterhout et  al. (27), which reviewed all of the 
carcinogenicity studies from 1979 when GLP was introduced, 
although it was not possible to retrieve all of the studies covered 
in that paper, those submitted for marketing authorization in 
the Netherlands between 1995 and 2004, and those authorized 
via the EU centralized procedures between 2004 and 2014. The 
criteria used to identify valid pairs of rat subchronic (3- and/
or 6-month) studies and 2-year carcinogenicity studies were as 
described below.
ToxRefDB Database Structure
We have downloaded an empty version of ToxRefDB from the 
website of the US Environment Protection Agency (EPA), and 
we have used the structured organization to summarize all the 
data available for the carcinogenicity studies. We started our 
assessment based on the assessment report, but in cases where 
there was a lack of detail, we used the non-clinical expert report, 
non-clinical overview, or other parts from the dossier available on 
microfilm or electronically.
Comparison of Protocols of Subchronic 
Studies with Carcinogenicity Studies
Although similar criteria regarding overlap of dose range have 
been applied as previously reported by Reddy et  al. (25) and 
Sistare et al. (16) for inclusion of the studies, we have included 
all compound datasets available, as the impact of the pharma-
cological properties is expected to be largely independent of the 
matching of doses.
The database contained the dose levels used in the subchronic 
and carcinogenicity studies and the effects of the pharmaceuticals 
on body weight, organ weight, histopathology of a large set of 
organs and tissues, and results of genotoxicity tests in vitro and 
in vivo.
CRiTeRiA FOR POSiTive GeNOTOXiCiTY 
TeST ReSULT
Genotoxicity is usually tested with a battery of genotoxicity assays, 
as detailed in the ICH guidelines S2A and 2B revised in S2R2 (5). 
The outcome of these tests was taken from the assessment reports 
and was not re-assessed.
COMPOUNDS CLASSiFiCATiON AND 
DeSCRiPTiON OF STUDY OUTCOMeS
The pharmaceuticals were classified for pharmacology, and sub-
sequently, the histopathological outcome of the studies has been 
described. The results of genotoxicity studies were included to 
cover similar criteria as used by Sistare et al. (16).
Pharmacological Criteria
The pharmacotherapeutic areas were based on target organs, such 
as central nervous system (CNS), cardiovascular system (CVS), 
respiratory system (RS), metabolic system (MB), hormonal sys-
tem (HM), gastrointestinal system (GIS), immunological system 
(IS), and antimicrobials (AM) (divided into antibacterials, anti-
malarials, antivirals, antifungals, and remaining compounds). 
Each pharmacotherapeutic category was subdivided into classes 
according to the primary drug target of the compounds in 
accordance with Stefansdottir et  al. (28). Small molecules may 
exert additional pharmacological activity at a higher dose, which 
is termed secondary pharmacodynamics and could, as described 
by Keiser et al. (29), be responsible for the carcinogenic response.
Histopathological Criteria
Positive histopathology observations were scored if any of 
the selected histopathological changes were reported as being 
increased in the subchronic toxicity studies, i.e., cellular hyper-
trophy, cellular hyperplasia, presence of altered hyperplastic foci 
of cellular alteration (atypical) cell foci (basophilic; acidophilic 
foci), cellular proliferation, and dysplasia. Furthermore, any 
changes in body weights and organ weights changes were noted.
The compounds were scored as negative for histopathological 
evidence of potential preneoplasia when the aforementioned 
histopathological changes were absent or not considered as being 
increased by treatment. All incidences reported to be higher than 
TABLe 1 | Summary of the observations in the subchronic and carcinogenicity studies.
# Mode of action Cat 
His
Cat 
Ph.
Fin 
Cat.
weight Subchronic Carcinogenicity
HT HP
231 AB, fluoroquinolone FN NT FN col; kid – – hsyst leu
244 AB, fluoroquinolone FN NT FN – – – pan tu
263 AB, fluoroquinolone FN NT FN ce; hrt; li; spl;  
adr; ova
– – kid ac
226 AF, conazole derivative FN NT FN li li – li ad
236 AF, conazole derivative FN NT FN adr; li; hrt; kid; 
thy; lu; spl; pan; 
br; gon; ova
adr – soft t sar
279 AF, remaining, allylamine derivative FN NT FN hrt; adr – – tes tu; li ad; li ac
246 AV, CCR5 receptor antagonist FN NT FN – thyr – thyr ad
218 AV, hepatitis B-inhibitor FN NT FN – – – pan ad; pan ac; li ad; li ac; zymgl 
ca; br gli
220 CNS, 5HT2 antagonist FN NC FN – – – li ad
230 CNS, remaining, α2-delta agonist FN NC FN – – – pan ac; pan ad; tes ad; ut polyp
251 CNS, remaining, antidepressant FN NC FN – li; thyr – thyr ac; mam ca; li ad; li ac
217 CNS, remaining, COMT-inhibitor FN NC FN adr – – kid ad; kid ac
229 CVS, loop diuretic FN NC FN – – – thyr ad; pit ad
253 CVS, loop diuretic FN NC FN – – – tes ad; ut ac
284 CVS, loop diuretic FN NC FN – – – kid ac; kid ad
282 CVS, platelet aggregation inhibitor FN NC FN – li – thyr ad; adr bpha; ut ac; li ad; ova 
ad; mam ad
242 IS, remaining, imidazothiazole derivative FN NC FN – – – pit ad
206 AI, COX2 inhibitor FN TN TN li – – li ac
222 AI, COX2 inhibitor FN TN TN – li; thyr – thyr ad; li ad
260 AI, NSAID FN TN TN – – – tes ad;
234 BM, remaining, isoflavone FN TNa TN – – – pit ad; li ad
277 CNS, 5-HT1b/d agonist FN TN TN – – – adr bpha; tes ad
239 CNS, antiepileptic, Na-channel blocker FN TN TN adr; pit; kid; li – – adr bpha
204 CNS, benzodiazepine FN TN TN – – – thyr ad; thym lymph; ut schwan
248 CNS, benzodiazepine FN TN TN – li – thyr ad
205 CNS, opioid, μ-agonist FN TN TN – – – tes tu; hsyst leu
197 CNS, remaining, melatonin receptor agonist FN TNa TN – – – li ad; li ac
223 CNS, remaining, NMDA-antagonist FN TNa TN – – – tes ad
261 CNS, remaining, nootropic drug FN TNa TN – – – adr bpha
250 CNS, SNRI FN TN TN – li – thyr ad
276 CNS, SNRI FN TN TN kid – – tes ad
262 CNS, SSRI FN TN TN li – – ln lymph
208 CVS, ACE inhibitor FN TN TN kid; li kid – tes tu
266 CVS, ACE inhibitor FN TN TN – – – thyr ac
271 CVS, ACE inhibitor FN TN TN – – – kid ad
285 CVS, ACE inhibitor FN TN TN – – – mam fad
233 CVS, ACE inhibitor FN TN TN kid – – thyr ad; ut polyp
249 CVS, α1 agonist FN TN TN – – – tes ad
289 CVS, anticoagulant FN TN TN – – – pan ad/ca
203 CVS, β antagonist FN TN TN tes; adr; li – – pit tu
219 CVS, β antagonist FN TN TN kid – – skin SCP
243 CVS, β antagonist FN TN TN thyr; li; adr; kid – – li ad
255 CVS, β antagonist, FN TN TN – – – spl bhaem
200 CVS, calcium antagonist FN TN TN – – – ut polyp
(Continued)
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the controls were considered positive; with no access to all of 
the original study reports, no attempts were made to re-evaluate 
them in terms of whether or not they were statistically significant. 
When the histopathological changes were incorporated in the 
database, they were considered to be related to treatment and 
significantly increased.
We have scored greater organ weights, hypertrophy, and 
hyperplastic findings separately in Table 1. Furthermore, we have 
listed the tumors observed by describing the organ system and 
the histopathological appearance.
Step 1: Categorization Based on 
Histopathology
We have categorized all compounds on the basis of histopathology 
findings in chronic studies and their relation to tumor findings 
in the 2-year studies, similar, but not identical, to the criteria in 
# Mode of action Cat 
His
Cat 
Ph.
Fin 
Cat.
weight Subchronic Carcinogenicity
HT HP
235 CVS, calcium antagonist FN TN TN – – – tes ad
237 CVS, calcium antagonist FN TN TN ova – – tes ad
240 CVS, calcium antagonist FN TN TN – adr – mam fad; pit ad
256 CVS, calcium antagonist FN TN TN – – – thyr ad; thyr ac
247 CVS, calcium antagonist. FN TN TN li; hrt – – ut polyp; oral SCC
252 CVS, imidazoline agonist FN TN TN – – – adr tu
272 CVS, Na-channel block FN TN TN – li – thyr ad; tes ad; adr bpha; adr bpha
209 CVS, PDE3 inhibitor FN TN TN li; kid – – adr bpha
232 CVS, remaining, D1/α agonist FN TNa TN adr; kid – – pan ad
216 CVS, remaining, imidazole, PDE-inh FN TNa TN – – – adr bpha
225 CVS, remaining, quinolone vasodilator FN TNa TN li; thyr; adr; spl; 
pros; tes
– – adr bpha
198 CVS, remaining, renin inhibitor FN TNa TN – col – col ad; col ac
212 GI, 5HT4 agonist FN TN TN – – – tes tu; pit ad
269 GI, 5HT4 agonist FN TN TN – – – thyr ad; mam fad; pan ad; adr bpha; 
li ad; pit ad
210 GI, histamine H2 antagonist FN TN TN li – – tes ad
275 GI, histamine H2 antagonist FN TN TN – – – skin fibr
238 GI, remaining, sugar alcohol FN TNa TN – li – tes tu
194 MB, antidiabetic, α-glucosidase inhibitor FN TN TN – – – tes ad; kid ad; kid ac
195 RS, histamine H1 antagonist FN TN TN li; kid – – adr bpha
207 RS, histamine H1 antagonist FN TN TN – li – thyr ad; pit ac; li ac
264 RS, remaining, methylxanthine-derivate FN TN TN li – – tes tu; mam fad
268 UB, anticholinergic FN TN TN – li – ut polyp; kid pap
283 UB, anticholinergic FN TN TN – – – kid sar
287 UB, anticholinergic FN TN TN – – – skin sar
196 ZZ, remaining, retinoid, topical, keratinocyte FN TNa TN pit; adr – – adr bpha; thyr ad
274 CNS, DA2 agonist FN TP TP adr li – tes ad; skin fibr
245 CNS, DA2 agonist FN TP TP – – – tes ad; tes ca
265 CNS, DA2 agonist FN TP TP – – – pit ad; ut ac
270 CNS, DA2 agonist FN TP TP – – – tes ad
273 CNS, DA2 antagonist FN TP TP – – – islet ad; mam ac; pit ad
213 CNS, remaining, carbonic anhydrase 
inhibitor
FN TPa TP – – – UGT pap
278 CVS, α1 antagonist FN TP TP br; li; kid; hrt – – adr bpha; mam ac
259 GI, proton pump inhibitor FN TP TP – stom – stom tu; stom SCC; li ad
215 HM, dual 5-reductase inhibitor FN TP TP – – – tes ad
224 HM, dual 5-reductase inhibitor FN TP TP – – – thyr ad
221 HM, estrogen agonist FN TP TP – – – pit ad
281 HM, estrogen agonist FN TP TP – – – li ad; mam ca
254 HM, GnRH agonist FN TP TP – – – adr bpha; adr mpha; islet ad; tes ad; 
pit ad; pit ca
286 HM, GnRH agonist FN TP TP – – – pit ad; pit ca
257 HM, progestogen–estrogen contraceptive FN TP TP adr; li – – pit ad; mam ad; mam ac
214 HM, progesterone antagonist, birth cont FN TP TP li – – li ad; ut ac; mam ac
241 HM, remaining, aromatase inhibitor FN TP TP – li – ova gca; UGT pap
201 HM, selective estrogen modulator FN TP TP – – – kid ad; kid ac; ova ad
202 MB, fibrate FN TP TP – – – tes tu; adr bpha; li ac
211 MB, fibrate FN TP TP li; kid; hrt; adr; 
tes
– – pan ad; stom tu; li ad; li ac
267 MB, HMG-CoA reductase inhibitor FN TP TP – – – thyr ad; li ac
258 MB, remaining, inhib. growth hormone FN TPa TP – – – sk sar; ut ac
228 RS, β2 agonist FN TP TP – pan – thyr ad; thyr ac; ova leio; mam ac
280 RS, β2 agonist FN TP TP – – – ova leio
288 RS, β2 agonist FN TP TP lu; hrt hrt – ova leio; pit ad; pit ac
199 RS, β2 agonist FN TP TP li – – thyr ad
227 RS, corticosteroid FN TP TP – – – islet tu; adr bpha; skin sar
158 AB, remaining, bactericidal FP NT FP li; spl; kid; thyr – stom; ut; stom –
157 CNS, SSRI FP TN TN – li li –
159 CVS, α1 agonist FP TN TN – – mam –
145 CVS, α2 agonist FP TN TN – – thy –
TABLe 1 | Continued
(Continued)
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# Mode of action Cat 
His
Cat 
Ph.
Fin 
Cat.
weight Subchronic Carcinogenicity
HT HP
149 CVS, α2 agonist FP TN TN – – islet –
156 CVS, angiotensin II antagonist FP TN TN – – kid –
162 CVS, angiotensin II antagonist FP TN TN – kid kid –
147 CVS, β antagonist FP TN TN – adr thyr –
148 CVS, β antagonist/α1 blocker FP TN TN li – li –
151 MB, antidiabetic, remaining, SGLT-2 inhibitor FP TNa TN – kid kid –
160 MB, remaining, 3 β-hydroxysteroid 
dehydrogenase
FP TNa TN – adr adr –
154 RS, histamine H1 antagonist FP TN TN – – mam –
155 RS, histamine H1 antagonist FP TN TN li li pan –
153 UB, remaining xanthine oxidase inhibitor FP TNa TN – – thyr –
144 CVS, α1 antagonist FP TP TP – – mam –
161 CVS, α1 antagonist and 5-HT1A FP TN TP – – bm –
150 IS, immunosuppressive FP TP TP – – ln –
152 IS, immunosuppressive, mTOR inhibitor FP TP TP – stom; thyr stom –
146 MB, HMG-CoA reductase inhibitor FP TP TP – – li –
2 AF, remaining, benzimidazole TN NT TN – – – –
108 AI, COX2 inhibitor TN TN TN – – – –
72 AI, COX2 inhibitor TN TN TN – – – –
44 AI, NSAID TN TN TN kid – – –
45 AI, NSAID TN TN TN – – – –
50 AI, NSAID TN TN TN kid; spl – – –
64 AI, NSAID TN TN TN – – – –
74 AI, NSAID TN TN TN – – – –
83 AI, NSAID TN TN TN li; kid – – –
91 AI, NSAID TN TN TN hrt; adr; kid – – –
124 AI, NSAID TN TN TN – – – –
129 AI, NSAID TN TN TN – – – –
71 AI, NSAID, TN TN TN – – – –
7 AI, remaining TN TNa TN li – – –
122 AI, remaining, cytokine modulator TN TNa TN – – – –
73 AM, remaining, antimalarial TN NT TN – – – –
97 AM, remaining, antiparasite TN NT TN – – – –
123 AV, TN NT TN – – – –
135 AV, herpes genitalis TN NT TN – – – –
60 AV, immunostimulant TN NT TN li; kid; adr – – –
104 AV, nucleoside inhibitor TN NT TN – – – –
18 AV, protease inhibitor TN NT TN – – – –
55 AV, viral DNA polymerase inhibitor TN NT TN – – – –
3 BM, bisphosphonate TN TN TN – – – –
33 BM, bisphosphonate TN TN TN – – – –
87 BM, bisphosphonate, TN TN TN thyr; parath bo – –
28 BM, remaining, calcium-mimetic TN TNa TN – – – –
4 CNS, 5-HT1b/d agonist TN TN TN – thyr; li – –
107 CNS, 5-HT1b/d agonist, TN TN TN – – – –
95 CNS, 5-HT3 antagonist TN TN TN – – – –
24 CNS, antiepileptic, Na-channel blocker TN TN TN – li – –
49 CNS, antiepileptic, Na-channel blocker TN TN TN – – – –
65 CNS, antiepileptic, Na-channel blocker TN TN TN – li – –
66 CNS, antiepileptic, Na-channel blocker TN TN TN – li – –
5 CNS, benzodiazepine TN TN TN – – – –
142 CNS, benzodiazepine-like hypnotic TN TN TN – – – –
143 CNS, benzodiazepine-like hypnotic TN TN TN spl; li; kid; tes; 
hrt; pit
li – –
84 CNS, opioid, μ-agonist TN TN TN – – – –
132 CNS, opioid, μ-agonist, anticholinergic TN TN TN – – – –
85 CNS, opioid, μ-antagonist TN TN TN – – – –
86 CNS, opioid, μ-antagonist TN TN TN – – – –
75 CNS, opioid, remaining, κ agonist TN TNa TN – – – –
22 CNS, remaining 5-HT, 5-HT1-agonist TN TNa TN – – – –
56 CNS, remaining, acetylcholinesterase inhib TN TNa TN – sgl – –
TABLe 1 | Continued
(Continued)
6
van der Laan et al. Prediction of the Carcinogenic Potential of Human Pharmaceuticals
Frontiers in Medicine | www.frontiersin.org October 2016 | Volume 3 | Article 45
# Mode of action Cat 
His
Cat 
Ph.
Fin 
Cat.
weight Subchronic Carcinogenicity
HT HP
96 CNS, remaining, AMPA glutamate antagonist TN TNa TN – – – –
106 CNS, remaining, cannabinoid antagonist TN TNa TN – – – –
20 CNS, remaining, DA-NA uptake inhibitor TN TNa TN li; adr; thyr li – –
118 CNS, remaining, GABA-enhancer TN TNa TN – – – –
138 CNS, remaining, GABA-metab. inhib. TN TNa TN – – – –
81 CNS, remaining, MAO-A inhibitor TN TNa TN lu; kid; thyr; tes; 
ova
– – –
102 CNS, remaining, MAO-B inhibitor TN TNa TN – li – –
136 CNS, remaining, nicotine agonist TN TNa TN – – – –
137 CNS, SNRI TN TN TN – – – –
103 CNS, SNRI TN TN TN – – – –
29 CNS, SSRI TN TN TN – – – –
54 CNS, SSRI TN TN TN – – – –
112 CNS, SSRI TN TN TN kid li – –
88 CNS, SSRI, 5-HT antagonist TN TN TN – – – –
15 CVS, ACE inhibitor TN TN TN – – – –
69 CVS, ACE inhibitor TN TN TN – – – –
117 CVS, ACE inhibitor TN TN TN kid kid – –
13 CVS, angiotensin II antagonist TN TN TN – – – –
40 CVS, angiotensin II antagonist TN TN TN – – – –
23 CVS, angiotensin II antagonist TN TN TN – kid – –
10 CVS, anticoagulant TN TN TN – – – –
14 CVS, β antagonist TN TN TN – – – –
16 CVS, β antagonist TN TN TN – – – –
17 CVS, β antagonist TN TN TN hrt; li – – –
25 CVS, β antagonist TN TN TN pit; lu; hrt; spl; 
kid; adr; tes; 
ova; br
– – –
26 CVS, β antagonist TN TN TN – – – –
126 CVS, β antagonist TN TN TN – – – –
127 CVS, β antagonist TN TN TN – – – –
9 CVS, calcium antagonist TN TN TN hrt; kid adr – –
90 CVS, calcium antagonist TN TN TN spl; kid; ova;  
hrt; li; adr; br
– – –
92 CVS, calcium antagonist TN TN TN – – – –
93 CVS, calcium antagonist TN TN TN – – – –
38 CVS, class 1C antiarrhythmic TN TN TN thyr; li – – –
53 CVS, class 1C antiarrhythmic TN TN TN hrt; li – – –
6 CVS, endothelin antagonist TN TN TN – li; int; adr; mam nose; bm –
115 CVS, endothelin antagonist TN TN TN – – – –
105 CVS, imidazoline agonist TN TN TN adr; tes – – –
98 CVS, loop diuretic TN NC TN – – – –
100 CVS, Na-channel block TN TN TN – – – –
101 CVS, Na-channel block TN TN TN – li – –
77 CVS, PDE3 inhibitor TN TN TN adr – – –
99 CVS, platelet aggregation inhibitor TN NC TN – li; thyr – –
63 CVS, remaining, 5-HT2 antagonist TN TNa TN spl; li; kid; hrt; 
pan; br; thy; adr
– – –
141 CVS, remaining, β1 partial agonist TN TNa TN – – – –
36 CVS, remaining, hemostatic TN TNa TN – – – –
89 CVS, remaining, Nitr/K+ ATP agonist TN TNa TN – – – –
113 CVS, remaining, PDE5 inhibitor TN TNa TN – li; thyr – –
78 CVS, remaining, vasodilator TN TNa TN – hrt – –
110 CVS, vasopressin-2 agonist TN TN TN – – – –
131 CVS, vasopressin-2 agonist TN TN TN – – – –
121 GI, 5-HT4 agonist TN TN TN – – – –
48 GI, histamine H2 antagonist TN TN TN br; hrt; kid; tes; 
li; ova
– – –
94 GI, histamine H2 antagonist TN TN TN li; kid – – –
119 GI, remaining, anti-osteoporose agent TN TNa TN – – – –
32 GI, remaining, Fe-chelator TN TNa TN – – – –
TABLe 1 | Continued
(Continued)
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# Mode of action Cat 
His
Cat 
Ph.
Fin 
Cat.
weight Subchronic Carcinogenicity
HT HP
70 GI, remaining, opioid, μ-agonist TN TNa TN – – – –
30 GI, remaining, phosphate binder TN TNa TN – – – –
80 GI, remaining, synthetisch prostaglandin TN TNa TN adr; li – – –
8 IS, remaining TN NC TN – – – –
76 MB, antidiabetic, α-glucosidase inhib. TN TN TN – – – –
68 MB, antidiabetic, DPP4 inhibitor TN TN TN – thyr; li – –
111 MB, antidiabetic, DPP4 inhibitor TN TN TN – – – –
114 MB, antidiabetic, DPP4 inhibitor TN TN TN – – – –
139 MB, antidiabetic, DPP4 inhibitor TN TN TN – – – –
58 MB, antidiabetic, remaining, SU derivative TN TNa TN – – – –
130 MB, remaining, aldose reductase inhibitor TN TNa TN – – – –
43 MB, remaining, hypertriglyceridemia TN TNa TN – – – –
57 MB, remaining, lipid replacement TN TNa TN – – – –
1 MB, remaining, nicotinic acid derived TN TNa TN – – – –
61 RS, anticholinergic TN TN TN – – – –
128 RS, anticholinergic TN TN TN – – – –
11 RS, histamine H1 antagonist TN TN TN – – – –
12 RS, histamine H1 antagonist TN TN TN li; lu; hrt; kid; tes li – –
67 RS, histamine H1 antagonist TN TN TN – li – –
82 RS, remaining, leukotriene receptor 
antagonist
TN TN TN – – – –
116 RS, remaining, mast cell stabilizer TN TN TN – – – –
51 UB, anticholinergic TN TN TN – – – –
125 UB, anticholinergic and calcium antagonist TN TN TN thyr; adr; ova; li – – –
79 UB, remaining, oral β3 agonist TN TNa TN – li – –
62 ZZ, remaining, CFTR potentiator TN TNa TN – – – –
39 ZZ, remaining, prostaglandin E2 TN TNa TN – – – –
109 ZZ, remaining, protein kinase C-beta inhibitor TN TNa TN – – – –
59 CNS, DA2-antagonist/5-HT antagonist TN TP TP – – – –
19 CVS, α1 antagonist TN TP TP kid; br; tes – – –
34 CVS, α1 antagonist TN TP TP – – – –
133 CVS, α1 antagonist TN TP TP – – – –
41 GI, proton pump inhibitor TN TP TP – – – –
21 HM, GnRH agonist TN TP TP – – – –
42 HM, progestogen–estrogen contraceptive TN TP TP pit; thyr – – –
120 IS, immunosuppressive TN TP TP – – – –
140 IS, immunosuppressive TN TP TP – – – –
47 IS, immunosuppressive, mTOR inhibitor TN TP TP – thyr – –
52 IS, immunosuppressive, S1P antagonist TN TP TP – – – –
134 MB, antidiabetic, remaining, PPAR-γ TN TPa TP hrt; li li – –
46 MB, fibrate TN TP TP – – – –
27 MB, HMG-CoA reductase inhibitor TN TP TP – – – –
35 CNS, SSRI TN TN TN – – – –
37 CVS, ACE inhibitor TN TN TN – – – –
31 UB, anticholinergic TN TN TN – – – –
184 RS, remaining, antifibrotic TP NC  TN – adr adr li ad; ut ac
164 AI, NSAID TP TN TN – – kid; UGT adr bpha
181 CNS, 5-HT1b/d agonist TP TN TN kid – epi; tes thyr ad; pit ad; thy bthym
176 CNS, 5-HT3 antagonist TP TN TN – – – li ad; li ac
183 CNS, antiepileptic, Na-channel blocker TP TN TN kid; adr li kid li ac
174 CVS, ACE inhibitor TP TN TN thyr – kid pit ad; br ac; mes lip; pit ac
186 CVS, ACE inhibitor TP TN TN – kid kid ln bhaem
167 CVS, α2 agonist, ocular TP TN TN – int int pan ac; thyr ad; mam ad
165 CVS, calcium antagonist TP TN TN li li ln; thyr thyr ad
172 CVS, calcium antagonist TP TN TN – – col mam fad; adr bpha; tes ad; pit ad; 
mam ac; pit ca
182 AF, conazole derivative TP NT TP li; kid; spl; br; 
ova; thyr
– thyr tes tu; br astr; skin mel; mam ac
171 AV, guanosine analog TP NT TP – pit tes mam ac; skin sar
189 AV, protease inhibitor TP NT TP – thyr li; kid adr bpha
185 CNS, 5-HT2 antagonist TP NC TP li thyr; mam mam thyr ad; mam ac
TABLe 1 | Continued
(Continued)
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# Mode of action Cat 
His
Cat 
Ph.
Fin 
Cat.
weight Subchronic Carcinogenicity
HT HP
163 CNS, DA2-antagonist, benzamide TP TP TP – – mam pan ad; pan ac; adr bpha; mam ca; 
pit ca
188 CNS, DA2-antagonist, DA3 antagonist TP TP TP li – lu mam ca
177 CNS, remaining, electron transporter TP TPa TP – – stom SCC and basal ca
192 CVS, α1 antagonist TP TP TP – li; vag li; mam thyr ad; thyr ac
193 CVS, α1 antagonist TP TP TP – – mam mam ad; hsyst leu
169 CVS, remaining, hydrazinophthalazine TP TPa TP – pit thyr thyr ad; thyr ac
178 GI, proton pump inhibitor TP TP TP li; li; lu; stom li; stom; stom stom tes ad; tes ad
187 GI, proton pump inhibitor TP TP TP li; kid; stom; thyr; 
hrt; spl
li; stom; thyr stom adr bpha; tes ad; stom SCP; stom 
SCC; hsyst leu; pit ad
175 HM, GnRH agonist TP TP TP – – tes pit ad
180 HM, GnRH agonist TP TP TP br pit pit pit ad
166 HM, remaining, antiandrogen TP TP TP tes; adr li; ova; adr; thyr tes; ova te ad; thyr ad; ut ac
179 HM, selective estrogen modulator TP TP TP – – ova kid ac; ova ad
190 MB, HMG-CoA reductase inhibitor TP TP TP – li li; stom ut polyp
173 MB, HMG-CoA reductase inhibitor TP TP TP thyr – stom stom SCP; thyr ac; thyr ad
191 RS, β2 agonist TP TP TP – – nose ova leio; pit ad
168 RS, corticosteroid TP TP TP – – mam mam fad; li ac; br astr; li ad
170 RS, corticosteroid TP TP TP many; tes; br; 
hrt; kid; pit; li
li pan; ln pan ad; pan ac; bo most; li ad; li ac; 
li ac; mam ad; mam ac
aDecision on category is based on this single case.
TABLe 1 | Continued
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the work of Sistare et al. (16). The following four categories were 
identified:
 1. Compounds that were negative for histopathological findings 
considered to be putative preneoplastic in the subchronic 
study and in the carcinogenicity study were considered true 
negatives (TNs). Compounds inducing hypertrophy only in 
subchronic studies were scored as negative.
 2. Compounds that were positive for histopathology findings 
considered to be putative preneoplastic in the subchronic 
study, but negative for carcinogenicity, were classified as false 
positives (FPs).
 3. Compounds that were positive for both the presence of treat-
ment-related putative preneoplastic histopathological lesions 
in the subchronic study and the presence of treatment-related 
benign and/or malignant tumors in the carcinogenicity study 
were considered true positives (TPs).
 4. Compounds that were negative for histopathology findings 
in the subchronic study, but positive for carcinogenicity, were 
considered false negatives (FNs).
Step 2: Categorization Based on 
Pharmacology
For each pharmacological class, we have listed all compounds 
and the outcomes of the subchronic study and the carcinogenic-
ity study. We have counted the number of compounds in a 
pharmacological class and the number of compounds inducing 
carcinogenicity.
• A class of compounds was called positive, when 75% of the 
compounds were associated with tumor induction. These 
classes are listed in Table 3.
• A class of compounds was called negative, when 75% of the 
compounds were not associated with tumor induction. These 
classes are listed in Table 4.
• A class of compounds was called with mixed outcome, when 
more than 25%, but less than 75%, of the compounds were 
associated with tumor induction. These classes are listed in 
Table 5.
After considering the mode of action (also based on publicly 
available literature) leading to induction of tumors, we made an 
evaluation of the probability that the pharmacology would be 
the main mode of action causing the carcinogenicity. We have 
discussed this and added to the tables as the proposed final 
categorization.
ReSULTS
A total of 366 pharmaceuticals have been evaluated in the present 
study, of which 289 met the criteria described in Section “Materials 
and Methods” for defining valid pairs of rat subchronic (3 and/or 
6-month) and 2-year carcinogenicity studies.
Genotoxicity evaluation
In our dataset, 21 compounds were assessed as positive or 
inconclusive with respect to genotoxicity. To give a detailed 
description is not relevant, since this assessment is conducted 
initially during the assessment for marketing authorization. After 
discussions with the sponsor, and before making a decision about 
the authorization, it was agreed that the genotoxicity findings do 
not influence the risk for patients. We have therefore decided not 
to give any weight to these data. None of those compounds is 
intended to be given to patients with a life-threatening disease, 
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in which case a serious benefit would be judged to outweigh the 
genotoxicity risk as specified in ICH S1A (2).
Histopathological Classification
True Negative Compounds
One hundred forty-three (50% of the total) pharmaceuticals that 
did not induce putative preneoplastic lesions in the subchronic 
(3- and/or 6-month) study also did not cause treatment-related 
tumors in the carcinogenicity study (Table  1, third column). 
Ninety-nine of these 143 compounds (69%) did neither exhibit 
any effect on organ weight nor induce cellular hypertrophy in 
any organ (Table 1).
Ninety-one of the 143 TN compounds (31% of the total) 
demonstrated a greater weight of one or more organs, such 
as liver (n =  16); kidneys (n =  17); heart (n =  11); adrenals 
(n  =  10); spleen, ovaries, and brain (n  =  5); testes (n  =  7); 
thyroid (n  =  6); pituitary and lungs (n  =  3), or incidentally 
(n = 1) other organs, either or not in combination with cellular 
hypertrophy (2 substances in liver and 1 substance in kidneys). 
Twenty-six pharmaceuticals showed cellular hypertrophy in the 
liver (n =  13), thyroid (n =  5), adrenals (n =  2), and inciden-
tally in the kidneys, mammary glands, bone, salivary glands, or 
intestines.
Cellular hypertrophy was mainly observed in the liver 
(n = 17), in four cases accompanied by greater liver weight, but 
not accompanied by the development of benign or malignant 
hepatocellular tumors.
False Negative Compounds
Ninety-six (33% of the total) substances did not exhibit putative 
preneoplastic lesions in the subchronic study, whereas treatment-
related benign and/or malignant tumors developed in the carci-
nogenicity study.
Fifty-two of these 96 compounds (54%) induced benign 
tumors in a single organ (39) or in multiple organs (13), mainly 
testes (Leydig cell adenomas), adrenals (pheochromocytomas), 
pancreas (acinar cell adenomas), thyroid (follicular cell adeno-
mas), pituitary (pars distalis adenomas), and liver (hepatocellular 
adenomas). Incidental benign tumors were seen in mammary 
gland, skin, ovaries, urogenital tract, and spleen.
Thirty-five of the 96 compounds (36%) induced benign and 
malignant tumors in the same organ, mainly liver, thyroid, testes, 
mammary gland, and pancreas (9%), or in multiple organs (27%).
Nine of the 96 compounds (9%) induced malignant tumors 
only in a single or multiple organs. These malignant tumors 
comprised skin sarcomas; adenocarcinomas of the uterus, a 
localized lymphoma; adenocarcinomas in the kidneys; and 
leukemia.
Seventy-seven of the 96 compounds (80%) caused tumors that 
frequently occur spontaneously in rats of the age examined and 
most of them are not considered relevant for humans.
False Positive Compounds
Of the 50 compounds that induced putative preneoplastic 
(hyperplastic) histopathological lesions in the subchronic study, 
19 of these (38%) failed to induce treatment-related tumors in the 
carcinogenicity study.
For these FP compounds, the site of histopathological evidence 
(cellular hyperplasia) of risk for rat neoplasia was the mammary 
glands, kidneys, and liver (three compounds each); thyroid and 
pancreas (two compounds each); and adrenals, stomach, uterus, 
lymph nodes, thymus, and bone marrow (one compound each).
True Positive Compounds
Thirty-one substances (11% of the total number) induced puta-
tive preneoplastic (hyperplastic) histopathological changes in the 
subchronic study and treatment-related neoplasms in the carci-
nogenicity study. In only 13 out of these 31 compounds (42%), the 
hyperplastic lesion and the tumor developed in the same organ, 
whereas for the other 18 compounds (58%), the hyperplastic 
lesions observed in the subchronic study did not develop in the 
same organ as the tumor in the carcinogenicity study.
Four compounds caused mammary gland hyperplasia in the 
subchronic study and mammary gland adenomas or carcinomas 
in the carcinogenicity study. One compound caused mammary 
gland hyperplasia without the development of mammary gland 
tumors. This compound induced follicular cell adenomas and 
carcinomas in the 24-month study but no follicular hyperplasia 
in the thyroid in the subchronic study. Six substances induced 
mammary gland (fibro)adenomas and/or adenocarcinomas in 
the mammary gland without mammary gland hyperplasia in the 
subchronic study.
Pharmacological Analysis of the 
Carcinogenic Response
The 289 human pharmaceuticals in the dataset were distributed 
over therapeutic areas as indicated above (Table 1, fourth column). 
Most of the therapeutic areas are divided over several pharmaco-
logical classes, and all compounds are distributed through these 
classes. However, the compounds are anonymized (see Table 1) 
due to intellectual-property reasons. A similar approach was 
followed as for the previous paper on the PhRMA–FDA–JPMA 
dataset (PFJ dataset) (26).
CNS Drugs
DA2 Agonists [1], Refers to the Class in Tables 3–5
All four (245, 265, 270, and 274) were found to induce tumors 
in the sexual organs. For three compounds (245, 270, and 274), 
Leydig cell adenomas were observed, while for the fourth com-
pound (265), uterine carcinomas have been described. For one 
compound (274), skin fibromas were observed too, while for 
another (265), a decrease in spontaneous pituitary adenomas 
was seen. The dopaminergic DA2 agonists are associated with an 
increase of luteinizing hormone, and the fact that all four com-
pounds induced either testis tumors or uterus tumors confirms 
the association. In the PFJ dataset (26), only two compounds were 
included, with one showing the same tumor profile. Based upon 
the literature (30), we could find support for a pharmacodynamic 
relationship and so we categorized this class as TP.
DA2 Antagonists [2]
Three out of four (59, 163, 188, and 273) showed mammary gland 
adenocarcinomas (two TP and one FN). For one compound, this 
was the only type of tumor observed (188). A second compound 
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(273) induced in addition pancreatic acinar cell adenomas and 
pituitary adenomas. The third compound (163) induced adrenal 
pheochromocytomas, in addition to mammary gland carcino-
mas. In a 3-month study, mammary hyperplasia was observed 
for this compound making it a TP. The fourth compound (59) was 
a TN. It is well known that administration of dopaminergic DA2 
antagonists is associated with an increase in prolactin, resulting 
in mammary adenocarcinoma in rodents. Based on this pharma-
cological effect, we categorized this class as TP.
5HT1b/d Agonists [43]
Four triptanes (4, 107, 181, and 277) showed a rather mixed 
response. Two compounds (4 and 107) did not induce either 
tumors or hyperplastic responses after 6  months (TN). Two 
other compounds induced a variety of tumors, one (277) with 
benign pheochromocytomas and Leydig cell adenomas (FN), 
while with the other (181), thyroid follicular cell adenomas and 
thymomas were observed. However, with the latter compound, 
Leydig cell hyperplasia was observed at 6 months (TP). Effects 
on thyroid and testis (Leydig cell hyperplasia and adenoma) 
are likely be related to liver enzyme induction. In both cases, 
these effects cannot be related to the direct pharmacodynamic 
action, which is in agreement with the absence of proliferative 
effects (31). A  general category of TN is given to this class of 
compounds.
5HT3 Antagonists [44]
5HT3 antagonists (95 and 176) have an inhibitory effect on the 
growth of HT29 cells (32). Two 5HT3 antagonists showed differ-
ent responses, one (95) was TN, while the other (176) induced 
liver adenocarcinomas. As this is unrelated to its pharmacology, 
the class was categorized as TN.
Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) [47]
Four SNRIs (137, 203, 250, and 276) are included with two 
(137 and 103) as TN, while the other two compounds (250 and 
276) as FNs showed thyroid adenomas or testicular adenomas, 
respectively. As these tumors were not associated with primary 
pharmacology, this class was categorized as TN.
μ-Opioid Antagonists [26]
Two are included (85 and 86), both TN, and we categorized the 
class in this way.
CNS, Na+ Channel Blockers [46]
From six antiepileptics sharing the property of being sodium 
channel blockers (24, 49, 65, 66, 183, and 239), four are TNs, 
one compound (183) showed liver hyperplasia at 6 months and 
hepatocellular adenocarcinomas after 2  years (TP). The sixth 
compound (239) showed only adrenal pheochromocytomas after 
2  years (FN), which are not relevant for humans. The class is 
categorized as TN.
Selective Serotonin Reuptake Inhibitors [27]
Seven compounds (29, 35, 54, 112, 157, 262, and 88) are 
included. Five were TNs, with one of them (112) showing hepatic 
hypertrophy, but no hyperplasia, at 6  months. The sixth com-
pound (262) induced lymphoreticulum cell tumors (FN), while 
the seventh (157) only showed liver hyperplasia (FP). There is no 
direct relation with pharmacology, and the relevance for humans 
is estimated to be negligible. Therefore, selective serotonin reup-
take inhibitors (SSRIs) are categorized as TN.
μ-Opioid Agonists [42]
Of the three μ-opioid agonists, two (84 and 132) are TN, whereas 
one (205) compound showed testis tumors and leukemia (at a 
non-matching dose). As opiates are not associated with prolifera-
tive action, this group was categorized as TN.
Benzodiazepine(-Like) Compounds [45]
Three real benzodiazepines and two benzodiazepine-receptor 
agonists are in this class. Three (5, 142, and 143) are TN. One ben-
zodiazepine (204) showed treatment-related thymus lymphomas, 
thyroid follicular cell adenomas, and uterus schwannomas, espe-
cially at high dosages, while another (248) showed only thyroid 
follicular cell adenomas. The latter compound also induced an 
increase in thyroid weight at 6 months. As these effects were asso-
ciated with induction of liver metabolism rather than attributed 
to the primary pharmacology, this class was categorized as TN.
5HT2 Antagonists [16]
Two compounds (185 and 220) are included. Compound 185 
induced mammary gland hyperplasia after 3–6  months, and 
mammary gland adenocarcinomas and thyroid follicular cell 
adenomas after 2 years (TP). Compound 220 induced only liver 
adenomas and no effects at 6  months. There are signals that 
5HT2 antagonists induce an increase in prolactin, which might 
be responsible for the association with mammary gland tumors. 
This has also been discussed with the PFJ dataset (26). However, 
this relation between 5HT2-receptor blockade and prolactin is not 
without discussion, and in this case, compound 185 might have 
also anti-DA2 affinity. Because of this uncertainty with respect 
to the pharmacology, we did not apply a category based upon 
pharmacology for this class (NC).
Remaining 5HT Compounds
One compound (22), a 5HT1 agonist was TN. We maintained for 
the 5HT1 agonist the TN category.
Remaining Opioid Compounds
One κ-agonist (75) is a TN, which is what we categorized it too.
Remaining CNS Compounds
Seventeen compounds with a large variety of pharmacological 
targets remained. Nine TNs are a nicotine agonist (136), an 
acetylcholinesterase inhibitor (56), a GABA-enhancer (118), a 
GABA-metabolism inhibitor (138), a dopamine–noradrenaline 
reuptake inhibitor (20), a monoamine oxidase inhibitor A 
(MAO-A) (81), a MAO-B inhibitor (102), an AMPA glutamate 
antagonist (96), and a cannabinoid antagonist (106). Several 
FNs were also present. An α2δ agonist of the L-calcium chan-
nel (230) induced pancreatic acinar cell adenomas and acinar 
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cell adenocarcinomas, and Leydig cell adenomas in males and 
uterine endometrial polyps in females (33). A direct pharmaco-
logical explanation could not be found in relation to this recep-
tor (34). Therefore, we maintained a category FN. A melatonin 
receptor agonist (197) induced hepatocellular adenomas and 
carcinomas, and we gave a TN categorization because of the 
absence of an association with melatonin receptor stimulation. 
A COMT inhibitor (217) was associated with an increase in kid-
ney tubular adenomas and carcinomas. We maintained category 
FN, as the kidney effect is likely to be an off-target effect (i.e., not 
related to pharmacology). An NMDA antagonist (223) induced 
Leydig cell tumors. However, NMDA are usually negative (26) 
and therefore were assigned a TN category. A nootropic drug 
(261) was associated with adrenal pheochromocytomas, but 
categorized as TN, as these tumors are not relevant to humans 
(see below). A tetracyclic antidepressant (251) induced liver 
adenomas and thyroid follicular cell adenomas based upon 
induction of metabolism, and also mammary gland tumors, 
and therefore, we categorized this compound as FN, as there 
was obvious pharmacological explanation for the latter tumor. 
A carbonic anhydrase inhibitor (213) induced urinary bladder 
papillomas. These compounds are known to be associated with 
crystallization in rat urinary bladder, and we applied a category 
TP for this compound. An electron transporter (177) is labeled 
as TP inducing forestomach hyperplasia in 6-month studies 
and forestomach squamous cell and basal cell carcinomas in the 
2-year study.
Several CNS compounds were associated with adrenal 
pheochromocytoma, i.e., the DA2 antagonist 163, the NA-channel 
blocker 239, and the nootropic drug 261. Pheochromocytoma (a 
tumor developing from the chromaffin cells, which are the sites 
of synthesis and storage of catecholamines) is the most common 
neoplasia of the adrenal medulla in rodents. Pheochromocytomas 
are frequently found in a background of diffuse medullary hyper-
plasia. Compounds producing this feedback interference include 
lactose and sugar alcohols such as lactitol and Ca2+. High doses of 
low digestibility carbohydrates, such as mannitol, sorbitol, xylitol, 
and lactitol, have been reported to increase the absorption and 
urinary excretion of Ca2+ as well as the incidence of all types of 
proliferative lesions in the adrenal medulla. Hypercalcemia is 
known to increase catecholamine synthesis. Other compounds 
that might act via altered Ca2+ homeostasis and progressive 
nephrocalcinoses in aging rats include the retinoids. Vitamin D 
is the most potent in vivo stimulus, yet identified for chromaffin 
cell proliferation in the adrenal medulla. Vitamin D3 resulted 
in a fourfold to fivefold increase in bromodexoyuridine (BrdU) 
labeling (35) in the adrenal medulla (focal hyperplasia), leading 
to pheochromocytomas. In the PFJ dataset, we identified four 
vitamin D-analogs, all associated with adrenal pheochromocy-
toma (26).
Cardiovascular Drugs
ACE Inhibitors [33]
Eleven angiotensin-converting enzyme inhibitors showed a 
variety of classifications. Four (15, 37, 69, and 117) are TN. Two 
(174 and 186) are TP based on kidney hyperplasia at 6 months, 
and for one compound (174), pituitary gland adenocarcinomas 
and mesentery lipomas at 2 years, while for the other compound 
(186), benign hemangiomas were observed in the lymph node. 
Five compounds (208, 266, 271, 285, and 233) are FN with kidney 
adenomas in compound 271, mammary fibroadenomas in com-
pound 285, Leydig cell tumors in compound 208, thyroid follicu-
lar cell adenomas with compound 266, and thyroid follicular cell 
adenomas and endometrial polyps with compound 233. Van der 
Laan et al. (26) mentioned seven negative compounds. The kidney 
as the target organ of compound 271 suggests a pharmacological 
effect that might be related to kidney hyperplasia (juxtaglomeru-
lar hyperplasia), which was seen with compounds 174 and 186, 
as well as with angiotensin II antagonists (26). Mammary gland 
fibroadenomas, as seen with compound 285, are the most com-
mon spontaneous tumors in female rats in almost all the routinely 
used rat strains with incidences of up to 70% in carcinogenicity 
studies. Fibroadenomas do not progress to malignancy and are 
not considered to be relevant for humans, whereas mammary 
gland adenocarcinomas in rats may be more relevant (35, 36). 
It is important to consider that the windows of mammary gland 
susceptibility or mammary gland sensitivity are missed when 
exposure starts in adult nulliparous rodents as is routinely the 
case in bioassays with pharmaceuticals. The tumors induced by 
208 and 266 are likely to be associated with induction of liver 
metabolic enzymes. The variety of tumors seen with compound 
174 is complex. We have categorized the ACE inhibitors as TN 
in accordance with Van der Laan et al. (26) overruling all other 
categories for individual compounds.
Ca Antagonists [14]
Twelve Ca antagonists are included in this dataset. Four are 
TN (9, 90, 92, and 93). Two (165 and 172) are TP, the first with 
lymph node hyperplasia at 6 months and thyroid follicular cell 
adenomas after 2 years, and the other showed colon hyperplasia 
of the muscularis mucosa at 6 months and after 2 years Leydig cell 
adenomas in the testis, mammary gland fibroadenomas, adrenal 
pheochromocytomas, and pituitary adenomas and carcinomas. 
Six others compounds (200, 235, 237, 240, 256, and 247) are 
FN. Two compounds (235 and 237) induced Leydig cell tumors, 
one induced thyroid follicular cell adenomas (256), and one 
compound (240) was associated with pituitary gland adenomas 
and mammary gland fibroadenomas. Compound 200 induced 
uterine polyps, while compound 247 induced uterine polyps and 
oral mucosa squamous cell carcinomas. Calcium antagonists, 
especially dihydropyridines, are not associated with tumor induc-
tion (37). Eight out of 12 compounds in our dataset are associated 
with the induction of tumors. Two compounds (165 and 256) 
induced thyroid tumors only, and two (235 and 237) only induced 
testis tumors. Two compounds (172 and 240) induced mammary 
fibroadenomas and pituitary tumors. Compound 247 induced 
uterine polyps (as did compound 200) and specifically gingival 
squamous cell carcinoma. The latter phenomenon is reported for 
mibefradil (38), as being due to the oral intake as diet mixture, 
and not directly related to the pharmacological effect. Van der 
Laan et  al. (26) classified calcium antagonists as negative, in 
accordance with absence of induction of cancer in humans (39). 
We, therefore, categorized all Ca antagonists as TN, taking into 
account these considerations.
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Angiotensin II Receptor Antagonists [21]
Five compounds (13, 40, 156, 23, and 162) were included. Three 
compounds (13, 23, and 40) are TN, and two (156 and 162) showed 
juxtoglomerular hyperplasia at 6 months (FP). The induction of 
juxtaglomerular hyperplasia does not predict further develop-
ment to kidney tumors, which confirms the findings of Van der 
Laan et  al. (26), with a slightly different sample set (only two 
compounds overlap). We categorized the class as TN.
Adrenergic α1 Antagonists [34]
Eight adrenergic α1 antagonists (19, 34, 133, 144, 192, 193, 278, 
and 161) showed different target organs, with three TN (19, 34, 
and 133). Three compounds showed mammary gland hyperpla-
sia (144, 192, and 193) and two (193 and 278) mammary gland 
tumors. Two compounds (192 and 193) are TP with mammary 
gland hyperplasia at 6 months and mammary gland adenomas 
and mononuclear cell leukemia after 2 years. Two (144 and 161) 
are FP, with mammary gland acinar hyperplasia at 6  months 
for one (144) and bone marrow hyperplasia at 6 months for the 
other (161). One FN (278) showed after 2 years mammary gland 
adenocarcinomas and adrenal phaechromocytomas. A direct 
pharmacological explanation for this connection to the mam-
mary system is unknown at this time. In addition, a connection 
between α1 antagonism and mammary tumor formation is also 
unknown. A choice for the final classification TP is based on the 
effects on the mammalian gland, both after 6 months and 2 years 
for several compounds, despite the fact that we have no clear 
molecular mechanism. Further research is, therefore, important 
to study this possible association of α1 antagonism and mammary 
tumor formation.
Adrenergic α1 Agonists [35]
Two compounds are included; one (249) is FN with only Leydig 
cell adenomas (related to enhanced liver metabolism) at 2 years, 
while the other (159) was FP with mammary gland acinar hyper-
plasia at 6 months but no tumors at 2 years. TN was chosen for 
the final categorization.
Adrenergic α2 Agonists [36]
Three compounds (145, 149, and 167) are included, of which 
one (145) is a TN. Compound 149 is FP with hyperplasia of the 
islets of Langerhans in the pancreas, while compound 167 is 
TP with small intestines hyperplasia at 6 months and pancreas 
acinar adenocarcinomas, thyroid follicular cell adenomas, and 
mammary gland adenomas after 2  years. Three adrenergic α2 
agonists, therefore, showed variable effects. The islet cell hyper-
plasia seen with compound 149 might be related to the pancreatic 
adenocarcinoma seen with compound 167. A pharmacological 
target in the pancreas for this class is well known to be inhibitory, 
e.g., inhibiting insulin secretion. Other compounds in this class 
have been mentioned in the literature as negative (23, 26, 40), and 
therefore, this group is categorized as TN.
Adrenergic β-Antagonists [25]
Thirteen β-blockers (14, 16, 17, 25, 26, 126, 127, 147, 148, 203, 
219, 243, and 255) are included, with seven categorized as TN. 
Two FP (147 and 148) showed thyroid follicular cell hyperplasia 
or hepatocellular hyperplasia but no tumors. Of the four FN, 
compound 201 showed hepatocellular hepatomas, compound 
219 showed forestomach squamous cell papillomas, compound 
243 showed pituitary gland tumors, and compound 255 showed 
spleen vascular neoplasia. The carcinogenicity potential of 
β-blockers has been a debate from their early existence, especially 
with respect to pronethalol (41).The tumors found were heteroge-
neous and therefore probably not related to pharmacology. Snyder 
and Green (23) also mentioned a low incidence of compounds 
associated with tumors for this class (2 out of 10). This class was 
therefore categorized as TN overruling the FN compounds.
Anticoagulants [37]
Two anticoagulants (10 and 289) showed slightly different out-
comes. The tumor outcome of compound 289 was in fact not sta-
tistically relevant but was decided to be a safety signal. However, 
pancreatic acinar adenomas/carcinomas are usually not relevant 
for humans. Therefore, we applied a category TN.
Imidazoline Agonists [38]
Two compounds are included (105 and 252): one is TN, while 
the other is FN with adrenal phaechromocytomas and hind limb 
tumors after 2 years. The adrenal tumors seen with compound 
252 might be reflected by a greater adrenal weight for compound 
105, although this might be speculative. The human relevance is 
low anyway. Therefore, it was decided to categorize these as TN.
CVS, Na-Channel Blockers [39]
Of the three Na-channel blockers used in cardiac treatment (100, 
101, and 272), two were TN, compound 227 showed thyroid and 
Leydig cell adenomas, as well as adrenal pheochromocytomas. 
As these tumors are more related to drug metabolism, and not 
pharmacology, we categorized this class as TN.
Loop Diuretics [16]
Three of the four (98, 229, 253, and 284) compounds are FN 
with compound 284 causing kidney carcinomas, compound 229 
causing thyroid follicular cell carcinomas and pituitary gland 
adenomas, and compound 253 causing uterus adenocarcinomas 
and Leydig cell adenomas. Compound 284 is a FN, and its target 
organ suggests a pharmacological profile for the carcinogenesis. 
The target organs of the other loop diuretics are probably not 
associated with their pharmacology. As this positive relation-
ship was found for only one compound, we decided to leave the 
categorization for this class as undecided (NC: non-categorizable 
based on pharmacological target), with no change of the histo-
pathological categories.
Class 1C Channel Blockers [22]
Two compounds (38 and 53), are included, both are TNs, and 
we also applied this categorization to these based on their 
pharmacology.
Endothelin Antagonists [23]
Two compounds (6 and 115) are included, both are TNs. No 
proliferative effects are reported for these compounds, and we 
categorized them as TN based on pharmacology.
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Vasopressin-2 Agonists [24]
Two compounds (110 and 131) are included and both were TN. 
No proliferative effects are reported for these compounds, and we 
categorized them as TN based on pharmacology.
Platelet Aggregation Inhibitors [40]
Two compounds (99 and 282) are included. One (99) was TN. 
The other (282) showed a variety of tumors, such as thyroid fol-
licular cell adenomas, adrenal pheochromocytomas, hepatocel-
lular adenomas, and endocrine-related tumors such as uterine 
adenocarcinomas, ovarian adenomas, and mammary gland 
adenomas. Two platelet aggregation inhibitors had a different 
tumor response; the first was TN, whereas the other compound 
was FN because of a dopaminergic action as a secondary phar-
macological effect (42). These compounds were not categorized 
related to pharmacology (NC).
Phosphodiesterase 3 Inhibitors [41]
One compound (77) was TN, while with the other (209), adrenal 
pheochromocytomas were observed. Therefore, we decided to 
categorize the class as TN.
Remaining CVS Compounds
Eleven compounds with a variety on pharmacological targets 
remained to be categorized. A 5HT2 antagonist (63) is TN, as is 
a β1-partial agonist (141). Five other TNs are a nitrate agonist 
(89), a phosphodiesterase-5 inhibitor (113), a sodium-channel 
inhibitor, a hemostatic compound (36), and a vasodilator (nitric 
oxide agonist) (78). All compounds were maintained in the TN 
category. A hydrazine (169) is TP with thyroid follicular cell 
hyperplasia after 6 months and thyroid follicular cell adenomas 
and carcinomas after 2 years. Because of the thyroid hyperplasia 
(without any liver signal) after 6 months, we maintained the TP 
category in this case, although a relation with pharmacology 
needs to be substantiated. Four compounds are FN, i.e., a DA1/α1 
agonist (232) that induced pancreatic acinar cell adenoma, an 
imidazole PDE inhibitor (216) that was associated with adrenal 
pheochromocytomas, a quinolone vasodilator (225), and a renin 
inhibitor (198) that was associated with colon adenoma and car-
cinoma. However, the colon is unlikely to be a pharmacological 
target, as Kochi et al. (43) described an antagonistic effect for this 
relation. Therefore, we decided to give a TN category to this class.
Gastrointestinal System
Proton Pump Inhibitors [12]
Four compounds (41, 178, 187, and 259) are included, with one 
TN. One TP (187) showed stomach hyperplasia after 3 months, 
and monocytic cell leukemia, adrenal pheochromocytomas, 
pituitary adenomas, Leydig cell adenomas, and squamous cell car-
cinomas in the forestomach. Another TP (178) showed stomach 
hyperplasia at 6 months and Leydig cell adenomas at 2 years. The 
third compound (259) was associated with hepatocellular adeno-
mas and squamous cell carcinomas in the stomach. The fourth 
compound was TN. The stomach hyperplasia and squamous cell 
carcinoma are clearly related to the pharmacology of this class. 
Therefore, we decided that this class should be categorized as TP, 
overruling the TN case.
5HT4 Agonists [18]
From the three compounds (121, 269, and 212), one compound 
(121) is a TN, while the other two are FN with tumors in the 
2-year studies. Compound 269 showed Leydig cell adenomas 
and pituitary adenomas, while compound 212 showed thyroid 
follicular cell adenomas, mammary gland fibroadenomas, 
pancreatic acinar cell adenomas, adrenal pheochromocytomas, 
hepatocellular adenomas, and pituitary adenomas. The GI 5HT4 
agonists are likely to be associated with indirect metabolic effects 
on thyroid hormones (269) or testosterone (212). However, this 
can be debated for compound 269, but a direct pharmacological 
explanation is not known. We categorized all these compounds, 
therefore, as TN.
Histamine H2 Antagonists [49]
From the four compounds, two (48 and 94) are TN. The other 
two (210 and 275) are FN, with 275 associated with an increased 
number of skin fibromas, and the compound 210 with Leydig 
cell adenomas. Histamine H2 antagonists are used as gastric 
acid secretion inhibitors. Inhibition of gastric secretion might 
be associated with long-term induction of gastric carcinoids 
as associated with their pharmacological action. None of the 
compounds in this dataset showed this effect. Therefore, these 
were categorized as TNs, although in the previous paper, the H2 
antagonists belonged to the positive class.
Gastrointestinal, Remaining Compounds
Five compounds remained in this class, and four were categorized 
as TN, i.e., a synthetic prostaglandin (80), a phosphate binder 
(30), an imaging/anti-osteoporose agent (119), and a Fe-chelator 
(32). A sugar alcohol (compound 238) is associated with Leydig 
cell adenomas (FN). As this is a rather unspecific effect, the 
compound was categorized as a TN.
Hormonal System
GnRH Agonist [3]
From the five compounds (21, 175, 180, 254, and 286), one is TN 
(21) while two are TP (175, 180), one with pituitary hyperplasia 
(180) after 3 months and pituitary adenomas after 2 years, and the 
other showed Leydig cell hyperplasia after 6 months and pituitary 
adenomas after 2 years. Two compounds (254 and 286) are FN, 
with no hyperplastic effects after 6 months, but both associated 
with pituitary adenomas and carcinomas after 2  years. One of 
these compounds (254) showed in addition Leydig cell adeno-
mas and pancreatic islet cell adenomas, and adrenal benign and 
malignant pheochromocytomas. The relation between pharma-
cology of GnRH agonists and the pituitary tumors observed for 
four compounds is clear, as the target organ is the pituitary (44). 
Only one compound (21) is TN, but we categorize all as TP based 
upon the similar pharmacology as the other members of the class.
Estrogen Agonist [4]
Two compounds (221 and 281) are included; one compound 
(221) with pituitary gland adenomas, and the other (281) with 
mammary gland carcinomas and hepatocellular adenomas. For 
the estrogen agonists, the identity of the target organ supports a 
pharmacological relationship. Estrogen agonists are important as 
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potential human-relevant carcinogens based upon IARC evalua-
tions (45), and we categorized this class, therefore, as TP.
Selective Estrogen Receptor Modulators [5]
Two compounds (179 and 201) have a similar tumor profile, i.e., 
kidney adenocarcinomas and ovary adenomas. Only one (179) 
showed ovary hyperplasia after 6 months making it a TP, while 
the other (201) was an FN. We categorized this class as TP.
Dual 5-Reductase Inhibitors [6]
Two compounds (215 and 224) are included, and these are FN. 
One compound induced Leydig cell adenomas, while the other 
induced only thyroid follicular cell adenomas. Because of their 
hormonal action, we categorized these compounds as TP, although 
the possibility that the tumors might be the consequence of just 
the induction of liver metabolism cannot be discounted.
Progestogen–Estrogen Combinations [7]
From the two combinations (42 and 257), one (42) is a TN and 
the other is a FN (257), with mammary gland adenocarcinomas 
and pituitary adenomas after 2 years. A pharmacological effect 
on the basis of estrogenic activity is considered to be likely, and 
therefore, we applied a TP category.
Hormones, Remaining Compounds
An antiandrogen (166) is a TP, with Leydig cell hyperplasia and 
ovary hyperplasia observed at a 3- or 6-month study. Leydig 
cell adenomas and thyroid follicular cell adenomas and uterus 
adenocarcinomas were seen after 2 years. An aromatase inhibitor 
(241) is FN, with urinary bladder papillomas and ovary benign 
stromal cell tumors after 2 years.
For all pharmacological classes associated with sexual hor-
mones, we conclude that such a relationship is likely to exist 
between pharmacological action and the induction of tumors, 
such as for the dual 5-reductase inhibitors (215 and 224), and 
the progestogen-containing combinations (42, 214, and 257). 
Therefore, we categorized all of these compounds as TP.
Immunological System
Immunosuppressives [29]
Six immunosuppressive compounds (120, 140, 150, 47, 152, and 
52) are all negative. Four compounds are TN and two FP. One 
of the FPs, compound 150, showed lymph node hyperplasia at 
6 months, and compound 152 showed stomach hyperplasia at 
6 months. The fact that all compounds are negative is remark-
able, as the immunosuppressive action is a well-known risk 
factor for the induction of cancer. Bugelski et al. (46) showed 
that around 50% of immunosuppressive compounds were 
associated with some type of cancer, probably based upon the 
spontaneous presence of oncogenic viruses. The absence of a 
carcinogenic effect for these immunosuppressive compounds 
could be explained by an absence of oncogenic viruses during 
these studies. It is known that immunosuppression is a real 
risk factor for human carcinogenicity. From that point of view, 
the ICH-S1 Expert Working Group indicated that compounds 
with an immunosuppressive risk could warrant a waiver in the 
future. Cyclosporin is also a class 1A (IARC) proven human 
carcinogen. Therefore, we decided to categorize the class of 
immunosuppressives as TP, despite the lack of tumors in these 
studies.
Immunomodulators [52]
Two compounds are included. Compound 8 is a TN, while 
compound 242 is a FN with pituitary adenomas noted at 2 years. 
Categorization of this class based on pharmacology remains 
uncertain. Therefore, we maintained the histopathological cat-
egorization for these compounds.
Metabolic System
Antidiabetics, α-Glycosidase Inhibitors [50]
Two compounds (76, 194) are included; one (76) is TN. The other 
has been studied in relation to glucose inclusion in the diet and 
as a pair-fed study. The study with glucose resulted in Leydig cell 
adenomas after 2 years, whereas without glucose, kidney tumors 
were observed. A final pair-fed study did not reveal any treat-
ment-related increase in tumors. As the target of α-glycosidase 
inhibitors is rather the intestine than the kidney, we concluded 
that this should be considered an off-target effect. We categorized 
this class, therefore, as TN.
Dipeptidyl Peptidase Inhibitors (DPP4 Inhibitors) [28]
Four DPP4 inhibitors (68, 111, 114, and 139) were all TN. 
Apparently, the inhibition of the breakdown of GLP-1 is only 
low and does not lead to the induction of thyroid C-cell tumors, 
as is known from GLP-1 agonists such as liraglutide (47). We 
categorized this class as TN.
PPAR-α-Agonists (Fibrates) [8]
Three compounds are included (46, 202, and 211). One is TN 
(46). Two are FN, with both compounds inducing hepatocellular 
carcinomas, accompanied with pancreas acinar cell adenomas 
and forestomach squamous cell carcinomas for compound 211. 
Compounds 46 and 202 showed Leydig cell adenomas and adre-
nal pheochromocytomas. Fibrates are known to target the liver, 
but the pancreas can also be listed as a target organ based on their 
class properties related to peroxisome proliferation (48). Because 
of the pharmacological profile, the histopathological categoriza-
tion TN and FN, respectively, was considered to be overruled by 
TP for this class.
HMG-CoA Reductase Inhibitors (Statins) [9]
Five compounds (27, 146, 190, 173, and 267) are included. One 
(27) is a TN and one (267) was a TN in Fisher rats but FN in 
Sprague-Dawley rats as hepatocellular adenocarcinomas and 
thyroid follicular cell adenomas were observed in this strain. 
Compound (146) was a FP with hepatocellular hyperplasia 
at 3  months, while compound (190) is a TP with hepatocel-
lular hyperplasia at 3 months (although only hypertrophy was 
observed in a 6-month study) and uterus endometrial polyps 
after 2  years. Compound (173) induced forestomach hyper-
plasia after 6  months, and thyroid follicular cell adenomas 
and carcinomas and forestomach squamous cell papillomas 
after 2 years. Whether or not all these tumors are related to the 
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pharmacological action of statins is not completely certain, as 
discussed in Ref. (26). In fact, the outcome is that statins can be 
expected to be carcinogenic anyway. Therefore, we categorized 
the complete class as TP.
Remaining Metabolic Compounds
Six remaining compounds are included. An antidiabetic sulfony-
lureum derivative (58), a lipid replacement (57), a nicotinic acid 
derivative (1), a triglyceride-lowering compound (43), a PPAR-
gamma agonist (134), and an aldose reductase inhibitor (130), 
are all TN. We gave the category TN to all these compounds 
as no other evidence for a proliferative effect on the basis of 
receptor stimulation could be found. A 3-betahydroxy derivative 
(160) and an SGLT-2 inhibitor (151) are FP, with adrenal gland 
hyperplasia in the cortex or kidney hyperplasia after 6 months, 
respectively. Thus far, no SGLT-2 inhibitor was associated with 
renal effects in rats (49, 50). An inhibitor of growth hormone 
(258) is FN with skin sarcomas and uterus endometrium carci-
nomas after 2 years.
Respiratory System
Anticholinergics [30]
Two anticholinergic compound (61 and 128) intended to be 
administered via the inhalation route are TN. Therefore, we cat-
egorized these compounds as TN based upon their pharmacology.
Adrenergic β2-Agonists [10]
Five compounds are included (191, 199, 228, 280, and 288). The 
most common feature was ovarian leiomyomas as seen for four 
of the five compounds. For the RS, the association of mesovar-
ian leiomyomas with β2-agonist is well described, although one 
compound (199) showed only thyroid adenoma. Even for recent 
long-acting β2-agonists such as indacaterol and vilanterol (51, 52), 
these tumors have been observed. A broader disturbance of the 
gender HM is clear from the mammary adenocarcinoma (228) 
and the effects on the pituitary (191 and 288). We categorized this 
class as TP based on pharmacology.
Corticosteroids [11]
Three compounds are included (168, 170, and 227). Two 
compounds (168 and 170) are TP. Compound 168 showed 
mammary gland acinar hyperplasia at 6 months, and at 2 years, 
mammary gland fibromas, brain astrocytomas, and hepatocel-
lular adenomas were observed. Compound 170 showed lymph 
node hyperplasia and pancreas islet cell hyperplasia at 6 months, 
and hepatocellular adenomas, pancreas acinar cell adenomas, 
mammary gland adenomas and adenocarcinomas, and bone 
osteomas and osteosarcomas were observed in the 2-year study. 
Compound 227 is a FN and showed pheochromocytomas, 
pancreatic acinar cell tumors, and skin fibrosarcomas. The 
relationship between the pharmacology of corticosteroids and 
the target organs observed is not easy to understand, but the 
wide distribution of corticosteroid receptors is in accordance 
with the broad list of organs bearing tumors, suggesting a broad 
pharmacological perspective. We categorized the corticosteroids 
as TP.
Histamine H1 Antagonists [48]
Seven compounds (11, 12, 67, 154, 155, 195, and 207) are 
included, with three TN (11, 12, and 67). Two FPs (154 
and 155) showed mammary gland acinar cell hyperplasia at 
3 months, while compound 155 showed islet cell hyperplasia and 
hepatocellular hypertrophy at 6 months. Only two compounds 
(195 and 207) were associated with tumors (FN). Compound 
195 showed pheochromocytomas, and compound 207 showed 
thyroid follicular cell adenomas, hepatocellular adenomas, and 
carcinomas. It is likely that these effects are associated with the 
induction of liver enzymes, based upon the target organs and 
the presence of pituitary adenomas and carcinomas. In general, 
the class is categorized as TN.
Remaining Respiratory Compounds
Compound 184, an antifibrotic agent, induced adrenal 
hyperplasia after 6  months, but liver adenoma and uterine 
adenocarcinoma after 2 years, making it histopathologically a TP. 
Pharmacologically, it could not be categorized, as no relationship 
is known to exist between the effects of the two endpoints. The 
effects are rather unspecific, and therefore, we finally decided to 
categorize it a TN. Compound 264 is a methylxanthine derivative 
is a FN with testis tumors and mammary fibroadenoma, rather 
than unspecific tumors, and therefore, we categorized this as TN. 
Compound 116 is a TN mast cell stabilizer.
Antimicrobial Agents
Antibiotics, Fluoroquinolones [13]
Three compounds (231, 244, and 263) are all FN. The first 
showed renal adenomas and carcinomas, the second showed 
leukemia, and the third was associated with pancreatic 
neoplasms. As the primary pharmacology is not directed to 
a mammalian target, we categorized these compounds as non-
mammalian target (NT).
Remaining Antibiotics
One compound (158), a bactericidal agent, is FP with forestom-
ach hyperplasia at 6 and 12 months.
Antifungal Agents, Conazole Derivatives [14]
Three compounds (182, 226, and 236) are included. The first 
(182) is a FN with skin, brain, testis, and mammary gland 
tumors. Compound 226 showed hepatocellular adenomas, and 
compound 236 showed a low incidence of soft tissue carcinomas. 
The classes of triazole antifungals do not have a mammalian 
target by definition, as discussed above. A specific effect on liver 
enzyme metabolism is described for related members of the class 
of antifungals (53). The first molecular event is not fully clear 
but might be the binding to a CYP450 subcategory. Conazoles 
induce hepatic cell proliferation in mice. We have categorized the 
antifungals as NT.
Remaining Antifungals
One compound (2) is a TN, while another (279) is a FN showing 
hepatocellular adenomas and carcinomas, as well as Leydig cell 
tumors. We categorized them all as NT.
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Antimicrobials, Remaining Antimicrobials
Two AM are included, an antimalarial drug (73) and an antipara-
sital compound (97) (anti-lice). Both compounds are TN. As the 
primary pharmacology is not directed to a mammalian target, we 
categorized these compounds as NT.
Antivirals [32]
The antivirals (18, 55, 60, 104, 123, 135, 171, 189, 218, and 
246) do not belong to the same class and have different types 
of therapeutic use and modes of actions. Six compounds, an 
immunostimulant (60), a nucleoside-analog (104), a viral 
DNA polymerase inhibitor (55), a protease inhibitor (18), a 
nucleoside combination (123), and an anti-herpes compound 
(135), are all TN. Four compounds (171, 189, 218, and 246) 
showed tumors. As antivirals do not have direct primary phar-
macological targets in mammals, as discussed above, the variety 
of effects might be due to completely different mechanisms 
of action. For compound 246, liver induction might have led 
to increased T3 metabolism, eventually resulting in thyroid 
tumors. A similar explanation is not possible for compounds 
171 and 218. In these individual cases, the potential human 
risk of the induction of tumors has been evaluated, and the 
relevance of these effects is negligible compared to the benefit 
of clinical treatment.
A CCR5 receptor antagonist (246) is FN with thyroid adeno-
mas after 2 years. A guanosine analog (171) is FN with mammary 
gland adenocarcinomas after 2 years. A protease inhibitor (189) 
is TP and showed hepatocellular hyperplasia after 6 months and 
adrenal pheochromocytomas after 2 years. As none of the antivi-
ral showed a clear connection to a mammalian pharmacological 
target, we just categorized them as NT.
Anti-inflammatory Compounds
Non-Steroidal Anti-inflammatory Drugs [19]
Twelve “classical” cyclooxygenase 1/2 inhibitors (44, 45, 50, 64, 
71, 74, 83, 91, 124, 129, 164, and 260) are included with 10 
being TN. One (164) compound is a TP with kidney hyperplasia 
at 6  months, and after 2  years, adrenal pheochromocytomas 
and hyperplasia in the urinary bladder were observed. The 
histopathological changes and tumors induced cannot be directly 
explained. The adrenal pheochromocytomas are assumed to be 
not relevant for humans. For another compound (260), it is 
assumed that induction of CYP450 would lead to an increased 
testosterone metabolism, which leads via a feedback mechanism 
to Leydig cell adenomas. We have categorized this class as TN.
Cyclooxygenase-2-Inhibitors [31]
Four compounds (108, 72, 206, and 222) are included. Two com-
pounds (72 and 108) are TN. The two other compounds (206 and 
222) are FN with hepatocellular adenomas and carcinomas. One 
compound (222) also showed thyroid follicular cell adenomas. 
The target organs suggest a relation with the liver-induced metab-
olism and not to a direct pharmacological response. This supports 
the negative properties of the NSAID (COX1/2-inhibitor) class, 
as discussed above. Based on this relationship, we categorized the 
class as TN.
Remaining Anti-inflammatory Compounds
Two compounds are included (7 and 122), which are both TN, 
and we categorized them the same.
Urinary Bladder
Anticholinergics [51]
Six compounds (31, 51, 125, 268, 283, and 287) are included, with 
three (31, 51, and 125) categorized as TN and three (268, 283, and 
287) as FN. Compound 268 was associated with benign uterine 
polyps and kidney papillomas, compound 283 with kidney 
sarcomas, and compound 287 with skin sarcomas, all with high 
dosages or incidental findings. The class was categorized as TN.
Remaining Urinary Compounds
A xanthine oxidase inhibitor (153) is FP with thyroid hyperplasia 
at 6 months. A β3-agonist (79) is TN. We have placed both in the 
category TN.
Bone Metabolism
Bisphosphonates [20]
Three compounds (3, 33, and 87) are included and shown to be 
TN. Van der Laan et al. (26) described a pharmacological expla-
nation for a positive finding, i.e., thyroid c-cell adenoma. This is 
not, however, confirmed in the present data, and we maintained 
the TN category.
Remaining Compounds Affecting Bone Metabolism
An isoflavone derivative (234) is a FN with pituitary gland 
adenomas and hepatocellular adenomas after 2 years. A calcium-
mimetic (28) is TN. As the tumor targets for compound 234 are 
rather unspecific, we categorized both as TN.
Remaining Compounds
Four compounds (39, 62, 109, and 196) remained pharmaco-
logically unclassified. Three were TNs, a prostaglandin E2-analog 
(39), a CFTR potentiator (62), and a protein kinase C-beta 
inhibitor (109). A retinoid for topical administration (196) is a 
FN, with adrenal phaechromocytomas and thyroid follicular cell 
adenomas after 2 years. As the tumor effects are rather unspecific, 
we assigned a TN category to this compound and maintained the 
TN for the others.
DiSCUSSiON AND CONCLUSiON
The present retrospective study using data from rat subchronic 
(3- and/or 6-month) toxicity and 2-year carcinogenicity studies 
obtained from the non-clinical assessment reports, available at 
the Medicines Evaluation Board of the Netherlands, was per-
formed to test independently a “weight-of-evidence approach,” 
expressed in the ICH Regulatory Notice Document (54) that was 
based on the “whole animal negative predictivity hypothesis” of 
Reddy et al. (25) and Sistare et al. (16). This might strengthen the 
assumption that the absence of any putative preneoplastic lesion 
in a subchronic study is associated with a negative outcome of 
a 2-year carcinogenicity study in rats, and therefore, no further 
long-term carcinogenicity study is needed. Furthermore, we 
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have evaluated the role of the pharmacological properties in this 
respect.
In order to build evidence for the possibility of prediction, 
we used information that is commonly available at the end of 
Phase  II  in the development of human pharmaceuticals for 
designing a 2-year carcinogenicity study, including data on phar-
macology and genotoxicity, and data from subchronic toxicity 
studies in rodents, as was undertaken earlier by Van der Laan 
et al. (26).
The dataset that we used has some overlap with the PFJ 
dataset as used by Van der Laan et al. (26), and we identified an 
overlap of 76 compounds. We decided to include these, as the 
application of more stringent criteria of putative neoplasm (see 
below) has led to differences in the categorization and to a higher 
number of FN.
Role of Liver Hypertrophy versus 
Hyperplasia
A large number of pharmaceutical compounds induced greater 
(relative) liver weight, and the question arises about the role of 
this property in the weight-of-evidence approach. A greater liver 
weight may result from a wide variety of causes such as hyperpla-
sia (of any of the resident cell types), hypertrophy, inflammation, 
fibrosis, abnormal storage of metabolism or cleavage products, 
neoplasia, and congestion (55–57). Typically, these changes do 
not occur in isolation, so in the absence of overt adverse changes 
such as inflammation, necrosis, or degeneration, it is important 
to recognize that an increase in liver weight may be induced by 
hypertrophy, hyperplasia, or a combination of the two (58). A 
xenobiotic that induces an increase in liver weight of 150% in a 
subchronic study might be considered to induce adverse effects 
in the context of dose setting for longer term studies but would 
not be considered to be adverse in the context of safety evaluation 
(59, 60).
In a survey of 139 chemicals used in the agrochemical indus-
try, Carmichael et al. (59) demonstrated that a relative greater 
liver weight of ≥150% of control values was correlated with 
the induction of liver tumors in mice. In a similar review of rat 
studies, a less statistically significant relationship between liver 
weight and hepatocarcinogenesis was noted, whereby greater 
liver weight alone correctly predicted 8 of 11 liver carcinogens 
(but falsely predicted 26 as positives) and failed to predict 3 
TPs (59).
Our findings demonstrate that treatment-related changes in 
organ weights, observed in a subchronic study with rats, are most 
likely non-specific and therefore should not be considered as a 
risk factor for neoplasia.
The histopathological diagnosis of hypertrophy can have 
various connotations, including a greater weight of the organ 
and an increase in the average size of the cells and even enzyme 
induction (functional hypertrophy). Allen et  al. (61) evaluated 
the results for 111 chemicals tested by the National Toxicology 
Program. If they applied hepatocellular necrosis, hepatocellular 
hypertrophy, hepatocellular cytomegaly, and greater liver weight 
as predictors for carcinogenicity, greater liver weight appeared to 
be the most sensitive parameter. However, chemicals that pro-
duced liver tumors frequently induced multiple morphological 
changes. They concluded that the best single predictor of liver 
cancer in mice was hepatocellular hypertrophy. They found no 
FNs, but numerous FPs, in their evaluation.
In the present study, 33 compounds with a TN label showed 
an increase in hepatocellular hypertrophy in the subchronic 
study that was not accompanied by development of hepatocel-
lular adenomas and/or carcinomas in the carcinogenicity study, 
whereas in only 7 cases was liver hypertrophy accompanied by the 
development of hepatocellular adenomas (3) or hepatocellular 
adenomas and carcinomas (4).
These observations support our starting point to classify 
hyperthrophy as an adaptive, rather than a putative, preneo-
plastic lesion. If we had assessed hepatocellular hypertrophy as 
an indicator for the development of hepatocellular tumors, 33 
compounds would have been overpredicted as potential liver 
carcinogens (FP substances). This confirms that liver hypertro-
phy observed in a subchronic study is an unreliable predictor of 
carcinogenicity. This is in agreement with the conclusion from 
the 3rd International ESTP Expert Workshop (62) that hepato-
megaly as a consequence of hepatocellular hypertrophy without 
histological or clinical pathological alterations indicative of liver 
toxicity is an adaptive reaction.
Histopathological evaluation
First, the predictivity was evaluated based upon the histopatho-
logical characterization.
The negative predictivity, the measure of the compounds 
evaluated that did not show any putative preneoplastic lesion 
in the subchronic studies and were negative in the carcino-
genicity studies, was 60%, whereas the sensitivity, a measure 
of the subchronic study to predict positive carcinogenicity 
outcome, was only 24% (Table 2). In contrast, the specificity, 
the accuracy of the subchronic study to correctly identify non-
carcinogens, was 88%. Based only on the absence of putative 
preneoplastic lesions in the subchronic study, 56% of the 2-year 
carcinogenicity studies could have been eliminated at the risk 
of 96 (33%) FN.
The positive predictivity (62%) is the percentage of compounds 
that showed putative preneoplastic changes in the subchronic 
study and caused treatment-related tumors in the 24-month 
carcinogenicity study.
Thirty-one substances were classified as TP. However, for 
only 13 compounds, the putative preneoplastic lesions devel-
oped in the same organs as the tumors. Eighteen compounds 
induced hyperplastic lesions in another organ than the organ 
where the tumors occurred. This observation is in agreement 
with the conclusion of Reddy et al. (25) that the whole animal 
approach assumes that preneoplastic changes at any organ will 
be indicative for an increase in tumor incidence in that organ 
or in any organ at a distant site. A closer look at the organs 
(Table  S1 in Supplementary Material: compounds 163–193) 
illustrates the importance of physiological relationships between 
organs. Several compounds induce their own metabolism in the 
liver and, as a consequence, enhance the enzymes responsible 
also for the metabolism of hormones, such as T3 and testos-
terone/estradiol, lowering their concentration. This decrease in 
hormone concentration leads to a feedback responses to the 
TABLe 2 | Predictivity of the subchronic toxicity study for the carcinogenicity of non-genotoxic pharmaceuticals.a
Carcinogenicity
Histopath. categoriz. Pharmacol. categoriz. Final categoriz.
Pos. Neg. Pos. Neg. Pos. Neg.
Subchronic tox Positive 31 19 62 21 (NT) 67 1
Negative 96 143 14 (NC) 192 17 204
% % %
False negatives =[96/(96 + 143 + 31 + 19)] × 100 33 5 6
Negative predictivityb =[143/(143 + 96)] × 100 60 93 92
Positive predictivityc =[31/(31 + 19)] × 100 62 75 98
Sensitivityd =[31/(31 + 96)] × 100 24 82 80
Specificitye =[143/(143 + 19)] × 100 88 90 99
aThe subchronic (3-month) study results were used to categorize a compound as true positive (TP), false positive (FP), false negative (FN), and true negative (TN).
bAbility to predict non-carcinogens: [TN/(TN + FN)] × 100.
cAbility to predict rat carcinogens: [TP/(TP + FP)] × 100.
dAbility to detect rat carcinogens: [TP/(TP + FN)] × 100.
eAbility to detect non-carcinogens: [TN/(TN + FP)] × 100.
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pituitary, resulting in enhanced secretion of thyroid-releasing 
hormone and/gonadotropin-releasing hormone, which in turn 
may lead to the development of tumors.
False Positive Compounds
Nineteen chemicals induced putative preneoplastic (hyper-
plastic) histopathological changes in the liver, thyroid, 
kidneys, mammary glands, pancreas, stomach, adrenals, and 
incidentally in other organs, whereas no tumors occurred in 
the carcinogenicity study, neither in the same organ nor in an 
organ at a distant site. This observation supports the conclusion 
of Jacobs (24), based on an evaluation of 60 pharmaceuticals, 
that various short-term indicators for carcinogenicity, such 
as hyperplasia, do not always result in tumors in that tis-
sue, although such putative preneoplastic histopathological 
lesions are generally considered a sign of potential concern 
for carcinogenicity.
Woutersen et  al. (63) performed a retrospective study and 
evaluated the subchronic (3 months) studies of 163 non-geno-
toxic chemicals with the aim to predict the tumor outcome of 
24-month rat carcinogenicity studies. In this study, the negative 
predictivity, a measure to predict a negative carcinogenicity 
outcome, amounted to 97%, whereas the sensitivity, a measure to 
predict a positive carcinogenicity outcome, was only 5%. Overall, 
this study supports the concept that chemicals showing no histo-
pathological risk factors for neoplasia in a subchronic study in rats 
may be considered non-carcinogenic and do not require further 
testing in a carcinogenicity study. The findings observed in the 
present paper with TP and FP compounds are in agreement with 
the conclusion of Reddy et al. (25) that more research is needed 
in order to achieve understanding of the biological links between 
putative preneoplastic lesions observed in a subchronic study and 
tumors developing at distant organ sites in the carcinogenicity 
study. The concept of adverse outcome pathways is helpful in 
this respect, defining as the first step the molecular event and 
then subsequent steps leading to the final outcome of tumors in 
different organs.
False Negative Compounds
Since it is generally accepted that the intention of screening assays 
should be conservative, it is most important that the number of 
FNs with respect to human carcinogens should be as low as pos-
sible. In the present study, 96 compounds were classified as FN 
because they did not show putative preneoplastic lesions in the 
3- and/or 6-month study but caused treatment-related tumors in 
the carcinogenicity study. These compounds are of concern with 
regard to the acceptability of the negative predictivity of the whole 
animal approach stating that the absence of evidence of putative 
preneoplastic lesions in all tissues in the 3- and/or 6-month study 
may serve as a strong negative predictor of tumor outcome in the 
carcinogenicity study.
When we evaluate these FN substances histopathologically, 
77 of the 96 FN substances appeared to induce benign tumors 
or benign and malignant tumors, which are considered not 
relevant for the human situation (36): acinar pancreatic tumors 
and islet cell neoplasia (36); pheochromocytomas of the adrenal 
medulla (64); forestomach tumors (65, 66); hepatocellular tumors 
induced by peroxisome proliferators (48, 67–69); fibroadenomas 
of the mammary gland (70); pituitary tumors (adenohypophysis 
tumors) (71); Leydig cell (interstitial cell) tumors of the testes (72, 
73); thyroid follicular cell tumors (74–76); and urinary bladder 
tumors (75, 77–80) and uterus tumors (endometrial stromal 
polyps) (81). That means that 19 FN substances still remain using 
this approach.
impact of Pharmacology
To evaluate further the remaining 19 FN substances, we 
compared this number with the outcome of an evaluation 
integrating the pharmacological properties of the compounds. 
We have tested the hypothesis that a pharmacological expla-
nation, as known for several years (30), and integrated in the 
histopathological approach recently (26), will help to reduce 
the number of FNs.
To study the role of the pharmacology in relation to histo-
pathology, we have evaluated whether the mode of action is 
TABLe 3 | Classes with high percentage of rat carcinogens (positive 
classes).
Class Total  
number of 
compounds
Compounds 
with  
tumors
Proposed 
final 
category
Related to direct pharmacology
1 CNS, DA2 agonists 4 4 (100%) TP
2 CNS, DA2 antagonists 4 3 (75%) TP
3 HM, GnRH agonists 4 4 (100%) TP
4 HM, estrogen agonists 2 2 (100%) TP
5 HM, selec. estrogen 
receptor mod.
2 2 (100%) TP
6 HM, dual 5-reductase 
inhibitors
2 2 (100%) TP
7 HM, progestogen 
(combinations)
3 2 (67%) TP
8 MB, HMG-CoA reductase 
inhibitors
5 3 (60%) TP
9 MB, fibrates 3 2 (67%) TP
10 RS, adrenergic β2 agonists 5 5 (100%) TP
11 RS, corticosteroids 3 3 (100%) TP
12 GI, PP inhibitors 4 3 (75%) TP
Not related to direct pharmacology
13 Antibacterial, 
fluoroquinolones
3 3 (100%) NT
14 Antifungal triazole derivatives 3 3 (100%) NT
15 CVS, calcium antagonists 12 8 (67%) TN
16 CVS, loop diuretics 4 3 (75%) NC
17 CNS, 5HT2 antagonists 2 2 (100%) NC
18 GI, 5HT4 agonist 3 2 (67%) TN
TABLe 4 | Classes with low percentage of rat carcinogens (negative 
class).
Class Total number 
of compounds
Compounds 
with tumors
Proposed 
final 
category
19 AI, NSAIDs 12 2 (17%) TN
20 BM, bisphosphonates 3 – TN
21 CVS, angiotensin II antag. 5 – TN
22 CVS, class 1C antiarrhytmics 2 – TN
23 CVS, endothelin antagonists 2 – TN
24 CVS, vasopressin-2 agonists 2 – TN
25 CVS, adrenergic 
β-antagonists
13 3 (21%) TN
26 CNS, μ-opioid antagonists 2 – TN
27 CNS, SSRIs 7 1 (14%) TN
28 MB, DPP4 inhibitors 4 – TN
29 IS, immunosuppressives 6 – TN
30 RS, anticholinergics 2 – TN
TABLe 5 | Classes with medium percentage of rat carcinogens (mixed 
outcome class).
Class Total  
number of 
compounds
Compounds  
with  
tumors
Proposed 
final 
category
31 AI, COX-2 inhibitors 4 2 (50%) TN
32 Antivirals 10 4 (40%) NT
33 CVS, ACE inhibitors 9 5 (55%) TN
34 CVS, adrenergic α1 antag. 8 3 (38%) TN
35 CVS, adrenergic α1 agonist 2 1 (50%) TN
36 CVS, adrenergic α2 agonist 3 1 (33%) TN
37 CVS, anticoagulant 2 1 (50%) TN
38 CVS, imidazoline agonists 2 1 (50%) TN
39 CVS, Na-channel blockers 3 1 (33%) TN
40 CVS, platelet aggreg. inhib. 2 1 (50%) NC
41 CVS, PDE3 inhibitors 2 1 (50%) TN
42 CNS, μ-opioid agonists 3 1 (33%) TN
43 CNS, 5HT1b/d agonists 4 2 (50%) TN
44 CNS, 5HT3 antagonists 2 1 (50%) TN
45 CNS, benzodiazepines 5 2 (40%) TN
46 CNS, antiepileptic, 
Na-channel blocker
6 2 (33%) TN
47 CNS, SNRIs 4 2 (50%) TN
48 RS, histamine H1 antag. 7 2 (28%) TN
49 GI, histamine H2 antag. 4 2 (50%) TN
50 MB, α-glycosidase inhibitors 2 1 (50%) TN
51 UB, anticholinergics 5 3 (60%) TN
52 IS, immunomodulators 2 1 (50%) NC
20
van der Laan et al. Prediction of the Carcinogenic Potential of Human Pharmaceuticals
Frontiers in Medicine | www.frontiersin.org October 2016 | Volume 3 | Article 45
related to a proliferative mechanism or only to non-proliferative 
mechanisms. We have selected those classes that are clearly 
related to induction of tumors as positive classes (Table 3) and 
classes not related to induction of tumors as negative classes 
(Table  4). A series of classes with mixed outcome have been 
evaluated in relation to literature, and for each pharmacological 
class, a clear outcome of “positive” or “negative” has been chosen 
(Table 5), meaning a high or low percentage of rat carcinogens, 
respectively. For the remaining individual compounds, we have 
taken into consideration the specificity of the tumors, i.e., those 
tumors likely to be associated with a change in metabolism of 
hormones (thyroid, or testosterone, or calciferol) are not related 
to a specific pharmacological mechanism. The compounds are, 
therefore, categorized as TN.
Based upon pharmacology, combined with a previous histo-
pathological categorization, we have given a final category in a 
separate column. This final category is applicable only to those 
classes for which at least two compounds are present in the 
dataset.
We have separated the compounds without a direct pharma-
cological effect in mammalian tissue from the other compounds.
Table 3 contains a list of pharmacological classes with a high 
percentage of rat carcinogens (positive classes). In line with the 
earlier overview (26), we can differentiate between carcinogenic-
ity directly related to pharmacology and carcinogenicity not 
related to pharmacology. Antibiotics, antifungals, and antivirals 
are developed to act against specific mechanisms in their target 
organism. Of course, it is possible that off-target effects exist in 
mammals. Apparently, this is true for the metabolic enzymes in 
liver. We have chosen, therefore, to give a separate classification to 
all compounds without a non-mammalian target (NT).
Based upon the identity of the organs bearing tumors (i.e., 
associated with liver, thyroid, adrenal, and testis), we have put 
the antibacterials, antifungals, and antivirals in the same category.
The calcium antagonists, the loop diuretics, and the GI 5HT4 
agonists are in the list of “not related to pharmacology.”
Combined evaluation of Histopathology 
and Pharmacology
In Table  1, we have incorporated the pharmacology-based 
categorization in the column labeled as Cat. Ph, by taking the 
TABLe 6 | Summarizing table based upon final categorization.
Histopathological categories  
(Table S3 in Supplementary Material)
Pharmacological categories  
(Table S4 in Supplementary Material)
Final categories  
(Table 1)
TN 143 192 (47a) 204 No preneoplastic signals in subchronic 
studies, no pharmacological signals, no 
carcinogenicity
TP 31 62 (5a) 67 Preneoplastic signals in subchronic studies, 
pharmacological signals, carcinogenicity
FN 96 17 Not conclusive
FP 19 1
NT 21
NC 14
Total 289 289 289
aSingle-in-class decisions.
NC, non-categorizable based on pharmacological target; NT, non-mammalian target in mammalian tissue; FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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pharmacology as an additional factor (Table  1, fifth column). 
In  this way, we categorized most of the compounds as TP (if 
belonging to a positive class) or TN, as explained above.
A combination of the histopathological categorization of the 
compounds together with the pharmacological categorization of 
the pharmaceuticals gave the following overall results:
• Twenty-one pharmaceuticals that do not have a mammalian 
target (8FN, 1FP, 9TN, and 3TP) are included.
• Fifty-two of the 96 FN compounds were recategorized as 
TNs based on pharmacology; 27 were recategorized as TPs; 
in addition to the 8 without mammalian target, 9 were not 
recategorized due to an unknown relationship between phar-
macology and carcinogenicity.
• Fourteen FP compounds were recategorized to TN based on 
pharmacology; five were recategorized as TP. One remained 
FP, as there is no pharmacological target.
• One hundred twenty-four TNs remained TN, while 14 were 
categorized as TP. Five were not categorized (NC).
• From the 41 TP compounds, 11 were recategorized as TN, 
while 17 remained TP on the basis of their pharmacology. Two 
could not be categorized, and three had no mammalian target.
• Finally, 14 out of 289 (5%) pharmaceuticals evaluated in the 
present retrospective study have not been recategorized. Nine 
are FN, and five are TN.
• After recategorization, based on both histopathology and 
pharmacology, the number of FN compounds was reduced to 
only 17 out of 289 (6%). The negative predictivity amounted to 
92%; the positive predictivity to 98%, and the sensitivity was 
80%, whereas the specificity amounted to 99% (TP: 67; FP: 1; 
FN: 17; and TN: 204) (see Table 6).
When the FN compounds that gave rise to tumors generally 
considered not relevant for human risk assessment, and those 
categorized as TN based on the pharmacological analyses, were 
moved from the FN category to the TN category, the negative 
predictivity of the 3- and/or 6-month study for the absence of 
carcinogenicity (the ability to predict non-carcinogens) amounts 
to 96% and the specificity (the ability to detect non-carcinogens) 
to 99% (Table 3).
The analysis of this paper clearly shows that adding phar-
macological properties as an additional factor of potential 
carcinogenicity gives a good prediction, reducing the number of 
FN substantially, which has consequences for the risk assessment 
of these pharmaceuticals.
CONCLUSiON
Our results demonstrated that subchronic (3- and/or 6-month) 
studies, in combination with knowledge of pharmacological 
properties, could appropriately categorize non-genotoxic phar-
maceutical into two categories:
(i) unlikely to be carcinogenic in rats if (1) no histopatho-
logical risk factor for neoplastic lesions observed in the 
subchronic study in any tissue, and (2) general absence of 
systematic, specific carcinogenicity in the pharmacological 
class.
(ii) likely carcinogenic in rats if (1) putative preneoplastic 
lesions observed in the subchronic study may give rise to a 
type of tumor in the rat 24-month carcinogenicity study that 
is irrelevant for humans; therefore, a carcinogenicity study 
has no additional value; (2) this is confirmed by the results 
from the pharmacological class.
We should keep in mind that the real focus is on the predic-
tion of carcinogenicity in humans, and we cannot quantify 
the full translational value of the rodent carcinogenicity 
study. However, overall, the results of this retrospective study 
support the whole animal approach as proposed by Reddy 
et  al. (25) and Sistare et  al. (16), especially with respect to 
the negative outcome of the subchronic studies as prediction 
for a negative outcome of a carcinogenicity study. Moreover, 
the results (predictivity) are consistent with the recent and 
similar investigation on chemicals (63). Furthermore, the 
data show the added value of the pharmacological evaluation 
of compounds in relation to potential class effects, both in 
the negative and positive direction. This evaluation strongly 
enhances the prediction of a possible impact for rodents 
and eventually for an extrapolation of the carcinogenic risk 
to humans. The outcome can be used to further prevent 
conducting unnecessary carcinogenicity studies. For most of 
the pharmacological mechanisms, it is well known that the 
non-genotoxic mode of action carries no risk of carcinogenicity 
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for the human situation because of important species-related 
differences between rodents and humans.
In this way, the pharmacological analysis confirms the 
approach recently published by Van der Laan et  al. (26) and 
reflected in the ICH Regulatory Notice Document to incorporate 
the pharmacological properties in predicting a positive and a 
negative outcome of a 2-year carcinogenicity study.
A high negative and a high positive predictivity of the carci-
nogenic potential of a pharmaceutical compound based on the 
findings in subchronic toxicity studies in rats, combined with 
knowledge of the pharmacological class, should result in waiv-
ing the need for conducting 2-year rat carcinogenicity studies, 
which will lead to a reduction in the numbers of animals used 
for scientific purposes and will save time and expense for drug 
development.
The dataset used for this analysis gives important opportuni-
ties for further research. As in addition to rat data, also mouse 
data are included, we can have a better understanding of the dif-
ferent outcomes between rats and mice, as discussed previously 
by Van Oosterhout et al. (27) and Friedrich and Olejniczak (15). 
Their reports point to the low regulatory relevance of lifetime 
mouse studies, and potential reduction of 2-year rat studies as 
proposed in the ICH RND (54), should at least be accompanied 
by measures with respect to 18- or 24-month mouse studies. 
Further discussion is recommended on the predictive value of 
the involvement of cytochrome p 450ies in the induction of cell 
proliferation in liver or other organs such as thyroid gland and 
testis. These and other questions require further analysis of the 
studies in this database.
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